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ABSTRACT
Mechanisms and Therapeutic Interventions for Breast Cancer-Induced Fatigue and
Mitochondrial Dysfunction

David Andrew Stanton

According to the latest statistics from the National Cancer Institute (NCI), about 1 in 8 U.S.
women (~13%) will develop invasive breast cancer over the course of their lifetime. This translates
to an estimated 268,600 new cases of breast cancer for the year 2019, and these diagnoses will
collectively make up 15% of all new cancer cases across all cancer types. The majority of these
women will experience the often-debilitating symptom of breast cancer-induced fatigue. these
patients often have difficulty performing normal activities of daily living, have decreased tolerance
to traditional tumor-directed therapies, and have higher rates of cancer recurrence. Additionally,
no effective drug therapies are currently in use for the treatment of breast cancer-induced fatigue.
This work aimed to identify molecular changes within the skeletal muscle of a variety of breast
cancer models. The downregulation of skeletal muscle peroxisome proliferator activated-receptor
gamma (PPARG) was consistently identified within breast cancer models, leading to altered
transcriptional networks in pathways that regulate various aspects of metabolic and mitochondrial
function. Breast cancer was found to induce mitochondrial oxidative dysfunction and aberrant lipid
metabolism within skeletal muscle. These changes were found to be independent of prior
treatment status, breast cancer molecular subtype, and weight loss. The identification of weight
stable changes in overall skeletal muscle transcriptional and mitochondrial function is a key
aspect of this work, and should be used to supplement future diagnostic guidelines and
intervention criteria within the field of cancer-associated cachexia. To address this dysfunction,
we targeted the transcriptional function of PPARG using the PPAR agonist pioglitazone. We found
that 2 weeks of pioglitazone supplementation was able to restore skeletal muscle transcriptional
networks and increase both mitochondrial ATP content and ATP synthase activity. This preclinical
data was used to serve as rationale and support for a recently approved clinical trial that will
examine pioglitazone supplementation in breast cancer patients. Mechanistically, preliminary
data suggests that this skeletal muscle transcriptional and mitochondrial dysfunction is caused by
tumor-derived factors such as miRNA containing exosomes. Collectively, this work demonstrates
that targeting skeletal muscle PPARG transcriptional activity in breast cancer represents a
promising therapeutic strategy to improve breast cancer-induced fatigue.
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Chapter 1
Specific Aims
Fatigue is one of the most common and debilitating side effects of breast cancer, with
direct consequences including skeletal muscle contractile dysfunction in the form of generalized
muscle weakness and inability to perform activities of daily living, impaired quality of life, and
reduced tolerance for tumor-directed therapies leading to the early cessation of chemotherapy
and radiation. This fatigue is a symptom of the multifactorial condition known as cancer cachexia,
which is characterized by systemic inflammation, metabolic dysfunction, and the progressive
atrophy of skeletal muscle and adipose tissue. This skeletal muscle atrophy is traditionally viewed
as the primary consequence of cachexia, but this is highly dependent on cancer type. Cachexia
is only present in 20% of breast cancer patients, despite over 90% reporting fatigue. This
discrepancy serves to highlight a distinct interaction of breast cancer and skeletal muscle
contractile function. There are no approved drug therapies to treat cachexia. Identifying the
mechanisms of breast cancer-induced muscle fatigue, is needed to develop effective therapeutic
strategies.
To investigate these mechanisms this project utilized patient-derived orthotopic xenografts
(PDOX) to generate a mouse model of breast cancer. Our lab has recently shown that this model
recapitulates the common clinical phenotype of breast cancer-induced skeletal muscle fatigue in
the absence of muscle wasting. RNA sequencing analysis of muscle from these mice revealed
transcriptional alterations within key skeletal muscle metabolic pathways, centered around the
downregulation of peroxisome proliferator activated receptor gamma (PPARG), a key metabolic
regulatory gene. Furthermore, mitochondrial dysfunction was confirmed within the skeletal muscle
of PDOX mice and in silico analyses identified several miRNA’s that are predicted to be upstream
regulators of the observed transcriptional alterations, including several with known PPARG
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binding affinity. Based on these preliminary data the central hypothesis of this application was
that breast carcinogenesis promotes skeletal muscle fatigue by inducing transcriptional
downregulation of PPARG within skeletal muscle, leading to the development of mitochondrial
dysfunction and consequently contractile dysfunction. The rationale for the proposed research
was that once the mechanism of PPARG downregulation has been identified, therapeutic
interventions, including the use of the FDA approved PPARG agonist pioglitazone, could be used
to attenuate skeletal muscle fatigue in PDOX mice. The following specific aims were proposed
and addressed by this dissertation work.
Specific Aim 1 was to determine the transcriptional and metabolic response of skeletal muscle
to breast tumor growth, and determine if these responses are rescued with pioglitazone
supplementation.
To address specific aim 1, we characterized the skeletal muscle transcriptional and mitochondrial
response to breast cancer in several models. This included the skeletal muscle of breast cancer
patients representing all breast cancer molecular subtypes, breast cancer PDOX mice, and in
vitro modeling with the C2C12 skeletal muscle myoblast cell line. We observed that each of these
models reproduced a transcriptional response that centered around the downregulation of
PPARG and subsequent alterations in PPARG target gene expression. This dysregulation
coincided with dysfunction in skeletal muscle oxidative function, lipid metabolism, expression of
mitochondrial proteins, and ultimately ATP production. We demonstrated that pioglitazone
supplementation in breast cancer PDOX mice was sufficient to restore transcriptional networks to
a profile resembling non-tumor bearing control mice, and to restore both skeletal muscle ATP
content and ATP synthase activity.
Specific Aim 2 was designed to determine if skeletal muscle dysfunction in breast cancer is due
to systemic tumor-derived factors which directly target skeletal muscle transcriptional and
metabolic regulation.
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To address specific aim 2, we developed and refined a protocol for isolating breast cancerderived exosomes. We then isolated the exosomal RNA and preformed RNA sequencing,
enriching for miRNA. We identified the upregulation of miRNA-27a-3p in breast cancer-derived
exosomes. As miRNA-27a-3p is verified to target PPARG, we characterized the response of
C2C12 cells to both isolated breast cancer exosomes and a miRNA-27a-3p mimic. We found that
exposure to breast cancer exosomes resulted in oxidative dysfunction and deduced skeletal
muscle ATP production, while miRNA-27-3p mimics were able to induce a similar response and
downregulate PPARG expression.
The data generated from these studies is significant because it characterized a unique breast
cancer-induced skeletal muscle phenotype, and provided a therapeutic intervention for the
observed phenotype. Our findings are novel, in that they highlighted systemic skeletal muscle
transcriptional and mitochondrial dysfunction in the absence of muscle wasting. This is important
for the field of cancer cachexia research, as it may influence future guidelines for diagnosis and
intervention. Additionally, we have demonstrated an effective pharmacological intervention using
an FDA approved drug, which is now being used in a phase 1 clinical trial at WVU. If successful,
this may represent the first FDA approved therapy for cancer cachexia.
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Chapter 2
Literature Review
Breast Cancer
Introduction
According to the latest statistics from the National Cancer Institute (NCI), about 1 in 8 U.S.
women (~13%) will develop invasive breast cancer over the course of their lifetime. This translates
to an estimated 268,600 new cases of breast cancer for the year 2019, and these diagnoses will
collectively make up 15% of all new cancer cases across all cancer types. In 2016, there were an
estimated 3,477,866 women living with breast cancer in the U.S. The ultimate impact of these

Figure 1.1: Modeled Trend Lines for Breast Cancer Incidence and Deaths. Data show both the rate of new breast cancer
cases/100,000 people, and the deaths resulting from those cases. Cancer trends reported in NCI publications are calculated
using the Joinpoint Regression Program to analyze rates calculated by the SEER*Stat software.

statistics is an estimated 42,000 deaths due to breast cancer in 2019, which comprises 7% of all
cancer deaths nationally1–3 Despite these statistics, the prognosis for breast cancer patients has
been improving over the years, and as of 2015 the 5 year survival rate following diagnosis is
approaching 90%, to go along with the increasing survival trend shown in Figure 1.1 (data from
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the NCI Surveillance, Epidemiology, and End Results Program (SEER 13)4. Furthermore, when
breast cancer is identified before metastasis, this 5-year survival rate increases to 99%.
These statistics are promising, and point towards increased effectiveness in both
screening and treatments for breast cancer. However, the symptoms of breast cancer and the
side effects of common treatments such as radiation and chemotherapy must be considered when
holistically examining the quality of life in patients. Several studies have examined the impact of
global quality of life scales in the overall prognosis of heterogeneous samples of cancer patients.
Global quality of life encompasses physical, social, emotional, and cognitive function and these
factors have been found to be independent prognostic indicators of survival in cancer patients5–9.
In terms of quality of life and personal autonomy, physical function is highly significant, and among
breast cancer survivors these quality of life considerations are becoming increasingly important
due to the high survival rate and prolonged life expectancy10. Common physical impairments
associated with breast cancer include fatigue, pain, weakness, and sexual dysfunction11. Fatigue
is reported in many breast cancer patients and is often present before the start of treatment 12,
and is also one of the most common symptoms associated with patients receiving adjuvant
chemotherapy13–18. Consequently, these patients often have difficulty performing normal activities
of daily living, which decreases their overall quality of life and personal autonomy. Additionally,
no effective drug therapies are currently in use for the treatment of breast cancer-induced fatigue.
This review will attempt to contextualize the importance of fatigue within the overall
pathogenesis of breast cancer, while first examining the clinical outcomes associated with this
observed fatigue and then discussing the physiological and molecular mechanisms that contribute
to the development of this condition. Finally, recent data describing transcriptional alterations in
breast cancer patients and experimental animals will be summarized and these data will be used
to examine the development of potential therapeutic interventions.
Breast Cancer-Induced Fatigue: Assessment
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The incidence of fatigue in breast cancer patients is both prevalent and debilitating, with
symptoms including pain, sleepiness, difficulty performing physical tasks, increased risk of cancer
recurrence, depression, and an overall decrease in quality of life19–21. Fatigue is present from the
early stages of cancer growth, and is often present upon initial cancer diagnosis. As evidenced
by the symptoms, cancer-induced fatigue is a broad condition, and as such there are numerous
definitions and diagnostic criteria that are used for assessment. Several of the currently used
diagnostic tools are presented in Table 1.1. The vast majority of these tools are self-reporting
questionaries’ and this method of fatigue quantification is currently viewed as the gold-standard.

Table 1.1: Common Diagnostic Tools for the Assessment of Cancer-Induced Fatigue. Some of the commonly used selfreported diagnostics scales administered to patients for the monitoring of fatigue.

Assessment Tool
Fatigue Severity Scale

(FSS)22

Measurement Focus

Diagnostic Type

Series of statements about life
domains that affect, or bring on,
fatigue. Yields a total fatigue severity
score

Self-reported, incidences over the
last two weeks

Multidimensional Fatigue
Symptom Inventory (MFSI)23

A series of statements designed to
assess the principal manifestations
of fatigue

Self-reported, incidences during the
last week

Piper Fatigue Scale24

Yields behavioral-severity, affective
meaning, sensory, and cognitivemood subscales and a total fatigue
score.

Self-reported, current feeling

Profile of Mood States (POMS)
Fatigue-Inertia Subscale25

Adjective checklist assessing
various psychological parameters
including fatigue-inertia. Yields a
total fatigue score.

Self-reported, incidences during the
last week
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European Organization for
Research and Treatment of
Cancer Quality of Life
Questionnaire Fatigue subscale
(EORTC QLQ C30 FS)26

The QLQ-C30 incorporates nine
multi-item scales: five functional
scales (physical, role, cognitive,
emotional, and social); three
symptom scales (fatigue, pain, and
nausea and vomiting); and a global
health and quality-of-life scale.

Self-reported, current

Functional Assessment of Cancer
Therapy Fatigue subscale (FACT
F)27

Assesses fatigue and anemiarelated concerns in people with
cancer.

Self-reported, current

While these scales are widely used and represent an opportunity for patients to describe
their symptoms, the condition of fatigue is still relatively vague. Because of this, several definitions
for cancer-related fatigue have been developed and are in use28,29. For example, one definition in
use states fatigue is: ‘a subjective state of overwhelming and sustained exhaustion and decreased
ability to perform mental and physical activities that is not relieved by rest 30. While fatigue is
generally quantified subjectively through the use of surveys such as those previously identified,
there are several clinical diagnostics that can be used to empirically measure the ability to perform
a physical task, including the six-minute walk test31, timed sit-to-stand test32, and the arm
movement test33. These tests allow for objective measures to be obtained and make it possible
for clinicians to evaluate the scope of the fatigue syndrome and also the effectiveness of any
ongoing treatments. The collective tools that are currently used are effective in identifying patients
who are experiencing fatigue and difficulty performing physical activities, but the recognition of
fatigue as an integral part of disease progression remains lacking. Coupled with the lack of a clear
consensus of what constitutes fatigue or fatigue syndrome, this poor recognition contributes to
physical deterioration in patients and progressively worse quality of life and ability to perform
activities of daily living. Because this cancer-induced fatigue has such impact on the lives of
cancer patients, it is important to consider this condition within the scope of overall treatment
programs, and to support this effort the treatment of cancer-related fatigue has recently been
identified as a priority by the National Institutes of Health34.
Cancer Therapy and Fatigue
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While fatigue is commonly present and impactful at the onset of breast cancer diagnosis,
the development or worsening of fatigue during treatment programs is also extremely prevalent.
Estimates of breast cancer-related fatigue during the initial stages of treatment range from
approximately 60%-90%, with higher frequencies reported in patients undergoing chemotherapy
(80% to 96%)14 than those receiving radiation treatment (60% to 93%)35,36. In another study,
patients undergoing chemotherapy were more than two-times more likely to report cancerinduced fatigue during treatment compared to patients receiving radiation therapy37.
The mechanisms that lead to fatigue during these treatment regimens are still poorly
characterized, but several studies have observed elevations in pro-inflammatory markers in
addition to fatigue29,38,39, which has led some investigators to hypothesize that activation of proinflammatory cytokines contributes to the fatigue seen during treatment. A study from Bower et
al. found that increases in serum levels of inflammatory markers CRP and IL-1 receptor antagonist
were associated with increases in fatigue40. Other studies have reported changes in IL-6
associated with changes in fatigue over the course of chemotherapeutic treatment 41, and
examination of inflammatory markers in patients undergoing combined radiation and
chemotherapy revealed fatigue and inflammation were correlated42. In addition to inflammation,
symptoms associated with chemotherapy including nausea, vomiting, and diarrhea can also
contribute to fatigue symptoms43. Examination of treatment and inflammation induced fatigue has
been robust, but a variety of other factors have been proposed to contribute to fatigue, including
anemia, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, five hydroxy tryptophan (5-HT)
neurotransmitter dysregulation, and alterations in adenosine triphosphate and muscle
metabolism44,45. These factors will be expanded upon in the discussion of central vs. peripheral
fatigue, and the mechanisms of skeletal muscle fatigue will be described in detail in a later section.
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A summary of factors that contribute to the development of cancer-induced fatigue are presented
in Figure 1.2.
Post-Treatment Fatigue
While fatigue is seen most often during the treatment phase, it is also observed in a large
subpopulation of breast cancer patients for a period ranging from months to years into
survivorship13,46. Specifically, about 30% of breast cancer survivors experience moderate to
severe fatigue after completion of the initial treatment47, and this fatigue has been shown to last
up to ten years post-diagnosis46. One of the most significant impacts of this enduring fatigue is
the decreased ability to perform physical tasks and activities of daily living29,48. This contributes to
an overall lack of physical activity which then contributes to greater levels of fatigue due to
inactivity, suggesting a self-perpetuating cycle if left unmanaged and untreated.
Fatigue Treatment

Anemia

HPA
dysregulation

Inflammation

(5-HT)
dysregulation

CancerInduced
Fatigue

Muscle
Metabolic
Dysfunction

Figure 1.2: Factors contributing to the development of fatigue in cancer. (HPA) hypothalamic-pituitary-adrenal, (5-HT) five
hydroxy tryptophan neurotransmitter dysregulation.
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Guidelines for the care and management of cancer-induced fatigue are available from the
National Comprehensive Cancer Network (NCCN)49, and the Oncology Nursing Society (ONS)50.
Currently, the most effective known treatment for cancer-induced fatigue is exercise. Numerous
trials and studies have evaluated the use of exercise as treatment in patients with various types
and severities of cancer and the results have been the subject of several meta-analyses51–53. A
recent meta-analysis of 274 exercise trials compared the effect of exercise compared to no
exercise in patients experiencing cancer-induced fatigue54. The authors showed that exercise had
a large effect on reducing fatigue in cancer survivors, and that aerobic interventions with high
adherence have the best results. Another study showed that exercise reduced fatigue in breast
cancer patients undergoing chemotherapy55. While exercise can improve quality of life and reduce
fatigue in cancer patients it must be prescribed appropriately in order to achieve those benefits.
Current NCCN guidelines recommend beginning with low intensity and low duration exercise and
to progress slowly. Despite guidelines, additional research is needed regarding both the safety
and customization of exercise regimens in different cancer populations.
Several other non-pharmacological methods are used for the treatment of cancer-induced
fatigue, including general patient education and counseling efforts, and cognitive-behavioral
interventions. For example, patients who are educated with methods including coping skills
training, nutritional counseling, and examination of physical sensory information show reductions
in fatigue levels56. For cognitive interventions, stress reduction and depression management are
key tools that can be used to reduce perceived fatigue57. Despite these strategies there are
concerted efforts to develop pharmacological therapies to address the underlying causes of
cancer-induced fatigue. Unfortunately, there are currently no drug-based therapies that are
consistently effective in reducing or eliminating fatigue and reduced functional capacity in patients.
The options that are used are usually specific to a certain aspect of the overall fatigue syndrome,
and are not intended to address the generalized reduction in physical capacity. Additionally, some
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of the treatments carry increased risk levels for adverse events such as the increased risk of
death, thrombotic events, red cell aplasia, and growth stimulation of certain tumor types following
the use of recombinant erythropoietin for anemia based treatment58. Other examples of drugs
used include the use of substances that manage sleep disturbances and insomnia in patients,
and drugs that are used for the treatment of emotional distress and depression. In the case of
sleep modulating agents there is little research in cancer patients and more trials are need to
assess both the safety and efficacy of these drugs59. Several studies examining the use of
selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase
(MAO) inhibitors, have been performed and have shown no significant effect on fatigue in the
absence of depressed mood49,60,61. Taken collectively, it is clear that addition research is needed
to examine potential therapeutic strategies that address cancer-induced fatigue, as there are
currently few options that specifically address this condition, and the options that are available
are of questionable value.
This dissertation will ultimately describe new research that will highlight a promising new
drug candidate to address this phenotype. The relationship between breast cancer-induced
fatigue and deficiencies in skeletal muscle mitochondrial function will be described, and the action
of the peroxisome proliferator activated receptor gamma (PPARG) agonist pioglitazone to
improve this function will be demonstrated.

Relation of Breast Cancer Stages & Subtypes to Fatigue
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The examination of breast cancer-induced fatigue should evaluate the potential effects of
the disease stage and cancer subtype. Breast cancer is characterized in a stage model from stage
Stage

Description
Non-invasive. No evidence of cancer cells or
non-cancerous abnormal cells breaking out
of the part of the breast in which they started,
or invading surrounding tissue.
Invasive breast cancer: stage IA describes
invasive breast cancer in which: the tumor
measures up to 2 centimeters (cm) and the
cancer has not spread to lymph nodes.
Invasive breast cancer: stage IB describes
invasive breast cancer in which: there is no
tumor in the breast but small groups of cells
are found in lymph nodes, or there is a tumor
in the breast that is no larger than 2 cm, and
there are small groups of cancer cells —
larger than 0.2 mm but not larger than 2 mm
— in the lymph nodes
Invasive breast cancer: stage IIA describes
invasive breast cancer in which: cancer is
found in lymph nodes near clavicle, small
tumor within axillary lymph node or the tumor
is larger than 2 cm but not larger than 5 cm
and has not spread to the axillary lymph
nodes
Similar to IIB but involves tumors larger than
5cm.
Invasive breast cancer: stage IIIA describes
invasive breast cancer in which either: no
tumor is found in the breast or the tumor may
be any size; cancer is found in 4 to 9 axillary
lymph nodes or in the lymph nodes near the
breastbone, tumor larger than 5cm and
cancer cells are found in lymph nodes.
Stage IIIB describes invasive breast cancer
in which: the tumor may be any size and has
spread to the chest wall and/or skin of the
breast and caused swelling or an ulcer and
may have spread to up to 9 axillary lymph
nodes.
Invasive breast cancer which has spread to
distal sites/organs. Often termed advanced
or metastatic breast cancer.

0

IA

IB

IIA

IIB
IIIA

IIIB

IV

Table 1.2: Stages of breast cancer and defining characteristics of each stage. Information for this table was obtained from
breastcancer.org. The breast cancer staging system, called the TNM system, is overseen by the American Joint Committee on
Cancer (AJCC).
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0 (pre-invasive disease) to stage IV (metastatic disease). The stages are summarized in Table
1.2., and are broadly characterized as low stage (0-II) and high stage (III-IV), with low stage
cancers having a better prognosis than high stage cancers. It is important to examine fatigue in
the context of these disease stages, as a thorough characterization of the onset and severity of
cancer-induced fatigue could be of clinical value for the planning of clinical intervention strategies.
Examination of the available literature reveals few studies have analyzed fatigue in the context of
the stage of the disease. Several studies have found no association between the stage of breast
cancer and fatigue. A study of Greek patients undergoing adjuvant radiotherapy found that fatigue
was independent of stage62, and another study of patients undergoing radiotherapy found fatigue
severity scores were not influenced by age, stage of disease, time since surgery, weight, or length
of time since diagnosis63. Several other studies have not found any relationship between fatigue
and stage64,65, but there are factors that must be considered when interpreting this data. First, the
primary concern of these studies was not to examine the relationship between fatigue and stage,
but rather to examine the relationship between fatigue and adjuvant therapy which has a known
association. Second, data have shown that fatigue is present among early stage breast cancer
patients66,67, suggesting that it is a clinical consequence that can be targeted earlier in the disease
progression or after adjuvant therapy. Therefore, the consideration of fatigue in late stage patients
is probably of less clinical value than addressing the more immediate concerns of the metastatic
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burden and prolonging lifespan. However, the recognition that fatigue is experienced early within
the progression of breast cancer presents clinical potential, both for aiding in the diagnosis of
cancer, but also in guiding therapeutic intervention to improve overall patient prognosis.
Breast cancer is divided into several subtypes, which have distinct morphological and
molecular characteristics as well as differing clinical implications. There are currently five intrinsic
subtypes as originally identified by Sorlie et al.68. The different molecular subtypes of breast
cancer are summarized in Table 1.3. The relationship between breast cancer-induced fatigue and
specific breast cancer subtypes is even less understood than disease stage. Because of the
Luminal A

Luminal B

HER2 Over-Expression

Triple-Negative/Basal Like

Normal-Like

Most common subtype and represents 50%60% of all breast cancers. Characterized by
higher levels of (ER) and lower levels of
proliferation related genes. Good Prognosis
Comprise 15%-20% of breast cancers and
have a more aggressive phenotype, higher
histological grade, proliferative index and a
worse prognosis. Increased expression of
proliferation-related genes (v-MYB), (GGH),
(NSEP1), and (CCNE1).
Accounts for 15-20% of breast cancer
subtypes. HER2 positivity confers more
aggressive biological and clinical behavior.
Highly proliferative, 75% have a high
histological and nuclear grade and more
than 40% have p53 mutations, poor
prognosis but greatly improved by targeted
therapy.
Represents from 8% to 37% of all breast
cancers, do not express ER, PR and HER2,
overexpress P-cadherin, fascin, caveolins 1
and 2, alpha-beta crystallin and EGFR, often
have BRCA1 mutations.
About 5%-10% of all breast carcinomas.
Poorly characterized, lack the expression of
ER, PR and HER2, but not basal-like
because they are negative for CK5 and
EGFR.

Table 1.3: Molecular subtypes and characteristics. (v-MYB), gamma glutamyl hydrolase (GGH), lysosome-associated
transmembrane protein 4-beta (LAPTMB4), nuclease sensitive element binding protein 1 (NSEP1) and cyclin E1 (CCNE1),
human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor
receptor (EGFR), tumor protein 53 (p53), breast cancer 1 gene (BRCA1), cytokeratin 5 (CK5).
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connections between metabolic changes and fatigue, examining potential differences in fatigue
phenotypes between subtypes represents an intriguing future direction for research. It is known
that transcriptional and metabolic changes induced by breast cancer lead to the development of
fatigue67, and based upon this observation it is reasonable to hypothesize that there may be
differences in the etiology of fatigue between the different molecular signatures of the subtypes.
However, data from our laboratory suggest that while there may be differences in terms of
differentially expressed genes and pathway regulation between the subtypes, the observed
functional changes, i.e. fatigue, are induced in a similar manner among the subtypes66,67. Future
work should examine these relationships, with the goal of elucidating differences in metabolic
regulation and fatigue phenotypes, as well as developing different therapeutic strategies if
differences do exist.
Molecular and Physiological Basis of Fatigue
Introduction
Following the above discussion on the characterization and prevalence of cancer-induced
muscle fatigue, it is necessary to examine the molecular and physiological basis of fatigue, and
to differentiate between types of fatigue and their potential causes. Fatigue is divided into two
broad categories, termed central and peripheral fatigue respectively. These will be defined and
examined in the context of breast cancer. Finally, metabolic regulation and dysfunction in the
context of breast cancer and cancer cachexia will be discussed, with a focus on potential
therapeutic strategies elucidated during this dissertation research.
Defining Fatigue
Conceptually, fatigue is a condition that results in a reduction in the ability to perform a
task, both mentally and physically. This can manifest in the form of sleepiness, physical
exhaustion from exercise, mental fatigue due to stress, or simply the inability to will oneself to

15

start an activity. These symptoms are ones that everyone experiences, with sleep and relaxation
being able to alleviate and reverse these in most cases. This type of fatigue with rapid recovery

Figure 1.3: Fatigue index from an isolated EDL muscle stimulated ex vivo. EDL muscles from BC-PDOX-bearing mice, NSG control
mice, and PDOX-Con mice were stimulated ex vivo using a repeated contraction protocol to analyze muscle fatigue properties in
response to BC-PDOX growth. The shape of the fatigue index curve from muscles of BC-PDOX mice was significantly different
than the curve from NSG control mice and PDOX-Con mice, especially during the first 80s of the protocol, with force output
declining rapidly from the initiation of the protocol. Data from Wilson et al. Extensor Digitorum Longus (EDL), Breast Cancer
Patient-Derived Orthotopic Xenograft (BC-PDOX), Nod-Scid-Gamma Immunocompromised mouse (NSG).

is known as acute fatigue, and is generally not harmful or pathological. On the other hand some
individuals experience chronic fatigue, which is defined as persistent physical or cognitive
tiredness that may last for months and is not alleviated by rest69. This is the type of fatigue that is
seen in pathological conditions, such as in breast cancer patients. This chronic fatigue is severely
limiting for these patients, as it often impairs their ability to perform normal everyday tasks, and
consequently has a large negative impact on their quality of life. The cognitive aspects of this
chronic fatigue are extremely limiting as well, and can lead to the development of conditions such
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as depression, but this review will focus on the physical aspects of muscular fatigue and how the
changes induced by breast carcinogenesis may lead to its development.
Muscular fatigue is the result of the decreased ability of a muscle to maintain force
production or power in response to a contractile stimulus. An example of a fatigue analysis
experiment is shown in Figure 1.3. The negative slope of the line is characteristic of the decrease
in force that is observed using electrical stimulation of an isolated muscle, following an initial
contraction. This curve will be examined in more detail in the discussion on mechanisms of fatigue
assessment.
Central Fatigue
The first category of fatigue is known as central fatigue, in reference to the contributions
of the central nervous system to muscle contraction. In exercise or simply normal movement
central fatigue broadly results from a failure to voluntarily activate a muscle, and more specifically,
refers to all factors that contribute to fatigue that are proximal to the peripheral nerve and
neuromuscular junction. These factors include excitatory input to higher motor centers, excitatory
drive to lower motor neurons, motor neuron excitability, and neuromuscular transmission70. These
aspects of the central nervous system make up a chain of events that lead to the propagation of
a stimulus from the motor cortex to the functional motor units of muscle. Defects at any level of
this chain can negatively impact the contractile ability of muscle. Relatively few studies have
examined the contributions of central fatigue to the overall cancer-related fatigue syndrome,
although there have been some recent studies that have attempted to gain further insight. Central
fatigue is generally measured by calculating muscle twitch force ratios by measuring an externally
stimulated twitch both before and after a fatigue task, such as repeated elbow flexion
movements71. This twitch force is able to estimate central fatigue because twitch force generation
is independent of the central motor drive, so comparison of its change with the changes in
maximum voluntary contraction provides the estimation of central fatigue. A recent study from
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Cai et al. found that twitch force ratios were elevated in cancer patients compared to controls,
suggesting that these patients experience more central fatigue than healthy controls, resulting in
the decreased ability to voluntarily contract muscle72. The mechanisms behind central fatigue
seem to be associated with the activity of neurotransmitters, including serotonin (5-HT), dopamine
(DA), acetylcholine, angiotensin II, noradrenaline (NA), and nitric oxide, with studies tending to
focus on 5-HT and DA73–80. Increased levels of 5-HT are associated with decreased performance
in studies of exercised rats81,81,82, while DA expression is known to counteract this fatigue83,84.
Studies in humans have yielded conflicting results, with a majority reporting no change in
performance when using exogenous 5-HT agonists85–87. Additionally, it is difficult to assess
neurotransmitter expression, as it is not possible to directly measure levels in the brain in living
subjects, thus the blood concentrations of some pituitary hormones such as prolactin,
adrenocorticotropin, and growth hormone are used as surrogates. In breast cancer patients, this
regulation could be impactful, as nearly 50% of breast cancer patients suffer from depression or
anxiety, and a cohort of these patients receive Selective serotonin reuptake inhibitors (SSRIs),
the first-line pharmacological treatment for depression88. These drugs work by increasing the
levels of serotonin in the brain, and consequently could impact the development of central fatigue
in these patients. This could warrant further study in the future, particularly because increased
mammary 5-HT has also been implicated in increased proliferative rates in breast tumors 89. The
mechanisms and incidence of central fatigue in breast cancer patients warrants further
investigation as a whole, and future studies should aim to expand on both the sometimescontradictory nature of previous results, as well as improving methodological quantification of
central fatigue.
Peripheral Fatigue
In comparison to central fatigue, both the mechanisms and quantification of peripheral
fatigue are better understood. Additionally, peripheral fatigue is the primary focus of this
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dissertation work, and thus thorough discussion of the sites of peripheral fatigue and the
mechanisms that lead to its onset is warranted.
Peripheral fatigue differs from central fatigue in that peripheral fatigue is induced through
deleterious alterations in the muscle itself, rather than changes within the nervous system. In
1984, Bigland-Richie90 identified the major potential sites of peripheral fatigue as neuromuscular
excitability, excitation-contraction (E-C) coupling, cross-bridge force and ATP hydrolysis, and
metabolic energy supply and metabolite accumulation. While each of these sites are important,
evidence suggests that in breast cancer, metabolic energy supply and regulation is potentially the
driving force behind the phenotypes observed in these patients.
Fatigue caused by peripheral cellular events originating at the cross-bridge and cell
metabolic pathways begins with the energetic demands needed for the working muscle to
maintain force production. With skeletal muscle activation, high energy phosphates, ATP, and
phosphocreatine all decrease, whereas Pi , ADP, lactate, and the H+ ion all increase as fatigue
develops. All of these changes have been suggested as possible fatigue inducing factors91,92. The
capacity for the skeletal muscle to sustain contractions and recover both acutely and over time
relies upon the ability of skeletal muscle to use a number of intra- and extramuscular substrates
to resynthesize ATP. These include creatine phosphate (CP), muscle glycogen, blood-borne
glucose, lactate and free fatty acids (FFA), derived from either adipose tissue or intramuscular
triglyceride stores. In the context of breast cancer patients, we must think about this regulation as
primarily responding to prolonged submaximal exercise, such as performing activities of daily
living. In this context the oxidative metabolism of carbohydrates and lipids within the mitochondria
supplies most of the ATP required for contraction, with muscle glycogen, blood glucose, and FFA
being the key fuels used93.
Carbohydrate and Lipid Metabolism
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During skeletal muscle activation in non-pathological states, muscle glycogen is the major
carbohydrate substrate during activity. With increasing duration of activation at a given intensity,
the rate of muscle glycogenolysis declines correspondingly with reduced glycogen levels and
increased blood-borne substrate (FFA) availability. The other primary source of carbohydrate is
blood-borne glucose and increased muscle glucose uptake during skeletal muscle activation94.
While glucose and insulin delivery to contracting skeletal muscle are increased due to increased
blood flow, this increase can only account for about 30% of the exercise induced increase in
muscle glucose uptake95, therefore muscle intrinsic factors play the major role. This includes
increased sarcolemmal transport of glucose, and facilitated transport by increased contractionstimulated GLUT-4 membrane localization. In breast cancer, aberrant metabolic regulation often
results in the development of insulin resistance96,97.
In insulin resistant states, insulin-stimulated glucose disposal in skeletal muscle is greatly
impaired, resulting in impaired carbohydrate metabolism, including impaired glucose transport
and glucose phosphorylation, and reduced glucose oxidation and glycogen synthesis98. The exact
mechanism the leads to the development of insulin resistance in skeletal muscle is still unclear,
however increased intramyocellar fat content and fatty acid metabolites have been shown to play
a major role99. This is intriguing, because this phenotype is also quite clearly demonstrated in the
skeletal muscle of cancer patients and various model systems of cancer. We have demonstrated
lipid deposition in C2C12 myotubes following exposure to breast cancer conditioned media100.
Increased lipid deposition has also been observed in the skeletal muscle of patients with
hepatocellular carcinoma101, gastric cancer102, colorectal cancer103, and breast cancer104. These
metabolic deficiencies may ultimately be responsible for the reduced capacity to resynthesize
glucose substrates needed to sustain sub-maximal contractile activity.
Mitochondrial Function in Health and Disease
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Due to the central relationship between mitochondrial function and our hypothesized
mechanism for breast cancer-induced fatigue, a general overview of mitochondrial structure and
function is warranted. Mitochondria are subcellular organelles that provide over 90% of the ATP
required for cellular metabolism105. This is particularly relevant in skeletal muscle, as the continual
supply and regeneration of ATP is required for the activity of key enzymes involved in membrane
excitability, sarcoplasmic reticulum calcium handling, and myofilament cross-bridge cycling106.
Intramuscular stores of ATP are kept at relatively low levels (5mmol/kg), and these stores are
unable to sustain contractile activity for extended periods. At submaximal exercise intensities,
these stores can be used in as little as 15 seconds (75% VO2 max), and even lower intensity
activity such as normal activities of daily living would quickly deplete this stored ATP if
replenishment did not take place. The vast majority of this replenished ATP comes from the
mitochondria, therefore any mitochondrial dysfunction or reduction in mitochondria content has
the potential negatively impact this energetic regulation and ultimately contribute to the etiology
of fatigue.
Mitochondrial Homeostatic Regulation
In a healthy cell, mitochondria maintain a balance between proliferation, termed
mitochondrial biogenesis, and degradation, termed mitophagy. Mitochondrial biogenesis is
governed by numerous transcription factors in response to diverse stimuli, including factors such
as nutrient availability, growth factors and hormones, toxins, temperature, and oxygen
fluctuations107. In the context of this dissertation work, the mechanisms of mitochondrial
biogenesis are particularly relevant as the PPARG transcriptional co-activator PGC1α is a master
regulator of this process.
PGC1α can increase global oxidative metabolism, a concept which has been introduced
and involves the process of cellular remodeling through mitochondrial and peroxisome
biosynthesis, which ultimately results in an increase in total mitochondrial content and
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subsequently increased oxidative metabolism108. PGC1α is able to induce mitochondrial
biosynthesis by activating various transcription factors, including NRF-1 and NRF-2, which in turn
promote the expression of mitochondrial transcription factor A, or TFAM. TFAM plays a critical
role in the process of mitochondrial biogenesis, as it drives transcription and replication of
mitochondrial DNA109.
In addition to its role in mitochondrial biogenesis, PGC1α is also associated with
transcription factors involved in the quality control processes of mitochondrial fusion and fission.
Growing evidence suggests that the delicate equilibrium between mitochondrial fission and fusion
is vital for many mitochondrial functions including metabolism, energy production, Ca2+ signaling,
ROS production and apoptosis. PGC1α has been shown to promotes mitochondrial fusion via coactivation of MFN2 expression110, as well as through increased expression of MFN1111. PGC1α
has also been shown to decrease the levels of DRP1, which is partly responsible for mitochondria
fission. Defects in these mitochondrial dynamics processes are involved in the pathophysiology
of a variety of cancers. Increased mitochondrial fission has been reported as a pathogenicity
factor in several distinct cancer models, including breast, lung, pancreatic, and thyroid
carcinomas, centered around the upregulation of DRP1 mediated fission112,113. This pathogenic
DRP1 regulation has been observed during both early stage cancer initiation and transformation,
and later metastatic stages suggesting a role for DRP1 in different stages of disease
progression114. The signaling pathways that lead to DRP1 activation in these different cancers are
distinct, suggesting a fundamental role for mitochondrial fission mediated by DRP1 in cancer in
the etiology of the disease.
In addition to mitochondrial fusion and fission dynamics, mitochondrial shape has the
potential to influence the cell’s susceptibility to apoptosis. It has been shown that DRP1 depletion
sensitizes cancer cells to apoptosis115. A key piece of evidence for the ability of mitochondrial
shape to determine apoptosis susceptibility come from a recent report, that showed with
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mechanistic evidence that small mitochondria are more resistant to MOMP compared to
intermediate and long mitochondria116. This suggests that excessive mitochondrial fission may be
an adaptation of cancer cells to avoid apoptosis, which may be a characteristic that is selected
for in cancer cell survival. These observations reinforce the potential of PPARG agonism as an
effective therapy in breast cancer. In addition to its role in attenuating fatigue and restoring skeletal
muscle mitochondrial function, the relationships between PPARG, PGC1α, DRP1, and
mitochondrial fission suggest that pioglitazone treatment may prove beneficial as a tumor directed
therapy as well.
Mitochondrial ETC and Energetic Regulation
Mitochondrial energetics are based on the availability of reducing equivalents, consumed
as carbohydrates and fats, that react with oxygen to generate water via mitochondrial oxidative
phosphorylation (OXPHOS). These substrates are processed within the mitochondria and
electrons are transferred from the reducing equivalents to the various complexes of the electron
transport chain (ETC). The energy that is released as the electrons flow down the ETC is used
to pump protons out across the mitochondrial inner membrane through complexes I, III, and IV.
This creates a proton electrochemical gradient, and the potential energy stored in this gradient is
used for several purposes including the import of proteins and Ca2+ into the mitochondrion, to
generate heat, and to synthesize ATP within the mitochondrial matrix. The energy to convert ADP
+ Pi to ATP comes from the flow of protons through the ATP synthetase (complex V) back into
the matrix. Matrix ATP is then exchanged for cytosolic ADP by the inner-membrane adenine
nucleotide translocators117. The efficiency with which dietary reducing equivalents are converted
to ATP by OXPHOS is known as the coupling efficiency. Variation in mitochondrial proteins has
been proposed to alter the OXPHOS coupling efficiency, thus altering the proportion of the
calories burned by the mitochondrion that are allocated to ATP generation versus heat production.
Alterations in the coupling efficiency can influence ROS generation, modulating Ca2+ uptake, and
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predilection to apoptosis118. This has obvious implications in our research and in breast cancer in
general, as we have observed downregulation of mitochondrial ETC proteins in these models.
Further, modulation of these proteins can be achieved through activation of PPARG
transcriptional activity, as many PPARG target genes are mitochondrial proteins.
Skeletal Muscle Mitochondrial Metabolism
Skeletal muscle metabolism is also largely reliant on the function of mitochondria. The
mitochondria is the most important site of ATP production within muscle, providing fuel for
myofibrillar contraction, maintenance of ion gradients, sarcoplasmic endoplasmic reticulum
atpase pump activity, among many others119. Skeletal muscle mitochondrial dysfunction has been
extensively studied in the context of type 2 diabetes, and examination of similarities between type
2 diabetes and breast cancer such as the development of insulin resistance may help elucidate
breast cancer-induced mechanisms of mitochondrial dysfunction.
Under normal conditions, insulin signaling has a stimulatory effect on mitochondrial gene
expression, an effect which is blunted in insulin resistant states120. A study by Halvatsiotis et al.
demonstrated that insulin treatment for 11 days had no effect on mitochondrial protein synthesis
rate and electron transport chain activity in patients with type 2 diabetes, whereas these were
increased in healthy controls. A study by Stump et al. similarly demonstrated that insulin infusion
failed to increase muscle ATP synthesis in patients with type 2 diabetes121, which may be related
to the intramuscular accumulation of lipid intermediates, which are known to disturb the insulin
signaling pathway122,123. Also, in this study, high-dose insulin infusion in healthy human subjects
increased mRNA transcripts levels for NADH dehydrogenase IV and cytochrome C oxidase
(COX) IV, which was not present in diabetic patients. In breast cancer, we have observed
dysregulation of metabolically significant transcriptional networks in the skeletal muscle of patient
derived orthotopic xenografted (BC-PDOX), tumor bearing mice124,125, as well as a significant
reduction in ATP from mitochondria isolated from skeletal muscle of these mice 124,125. In support
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of these murine observations, proteomics analysis in the skeletal muscle of HER2+ BC patients
revealed lower protein expression of nearly every component of the mitochondrial ETC and a
correspondingly lower ATP content in muscle biopsies from BC patients of multiple tumor
subtypes125. These data clearly demonstrate mitochondrial dysfunction in muscle of patients with
BC, which will directly impact the fatigability of skeletal muscle. These points, along with the data
presented in this dissertation, provide strong support for the hypothesis that breast cancerinduced fatigue is caused or exacerbated by altered metabolic control within the skeletal muscle,
and is particularly driven by mitochondrial dysfunction and reduced ATP content.
Skeletal muscle PPARG and Mitochondria
While these studies have demonstrated the role of skeletal muscle PPARG in the
regulation of insulin sensitivity, the effects of PPARG agonism on skeletal muscle metabolic
regulation remain poorly understood. One potential impact of PPARG in muscle is the regulation
of fatty acid transport into the mitochondria and increased fatty acid oxidation rates. Benton et al.
showed that seven days of TZD supplementation did not alter the rate of fatty acid transport into
muscle, but did increase rates of fatty acid oxidation in subsarcolemmal and intermyofibrillar
mitochondria141. The effects of PPARG activation were also studied in human skeletal muscle
following 8 weeks of rosiglitazone treatment in men with impaired glucose tolerance. Long-chain
fatty acid composition and stearoyl-CoA desaturase 1 were examined, ultimately demonstrating
a shift in lipid composition from saturated long-chain fatty acids to unsaturated fatty acids in
muscle142. In a study from Coletta et al. six months of pioglitazone supplementation in patients
with type 2 diabetes induced increases in AMPK and acetyl-CoA carboxylase phosphorylation
with pioglitazone, and increased expression of genes important in fat oxidation and mitochondrial
function143. To our knowledge, the work presented in this dissertation represents the first
demonstration of PPARG dependent improvements in skeletal muscle mitochondrial function in
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breast cancer and should prompt additional research into the systemic metabolic consequences
of tumor growth.
PPARG Structure Function and Role in Health and Disease
The mechanism by which breast cancer induces mitochondrial dysfunction appears to be
related to signaling by the PPAR proteins. PPARG has been previously identified as a potential
key regulator of BC-induced skeletal muscle fatigue using both human data and data generated
in the patient-derived orthotopic xenograft model of breast cancer100,124–126.
The PPAR proteins are lipid sensing, ligand-activated transcription factors that regulate
multiple metabolic processes throughout the body, with a particularly strong role in regulation of
glucose and lipid metabolism. PPARα is predominately expressed in tissues with high rates of
fatty acid catabolism, including liver, SkM, and cardiac muscle. PPARγ is highly expressed in
adipose tissue, is considered a master regulator of adipogenesis, and modulates insulin
sensitivity. PPARβ/δ is the least well-characterized of the PPARs, but it is ubiquitously expressed
in most tissues, regulates blood cholesterol and glucose levels, and is involved in fatty acid
oxidation127. Because PPARs play an obvious role in regulating whole body energy homeostasis,
there has been significant success in modulating these transcription factors for the benefit of
patients with diabetes, dyslipidemia, and atherosclerosis128; and promising anti-catabolic efficacy
has been observed with PPAR agonists in mouse models of Lewis lung carcinoma, colon
adenocarcinoma, and non-small cell lung cancer129–131.
PPARG is a nuclear receptor transcription factor, whose activity is regulated through the
direct binding of steroid and thyroid hormones, vitamins, and various lipids132,133. PPARG is
predominantly expressed in adipose tissue, where it plays a major role in regulating adipocyte
differentiation and lipid metabolism. Transactivation of PPARG is dependent upon the
heterodimerization of PPARG and the retinoic X receptor, while binding of agonist ligands to
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PPARG induces a conformational change that attracts transcriptional coactivators. Potent agonist
ligands of the PPARs include a class of compounds known as thiazolidinediones (TZDs) or
glitazones, which include rosiglitazone and pioglitazone. The action and consequences of these
drugs will be described in greater detail in a later section. In addition to classical transactivation
of target genes, PPARG can also negatively regulate gene expression through ligand dependenttransrepression. This mechanism antagonizes the pro-inflammatory NF-kB and AP-1 signaling
pathways by inhibiting the degradation of co-repressors in those pathways134,135.
PPARG in Skeletal Muscle
PPARG is expressed to a lesser extent in many other tissues, including skeletal muscle136,
where it plays various roles including the regulation of glucose metabolism and insulin sensitivity.
As PPARG levels are very low in skeletal muscle as compared to adipose tissue, it has been
postulated that many of agonist induced effects of PPARG activation in muscle could be the
indirect result of PPARG activation in adipose tissue137. However, evidence exists that indicates
a specific role for skeletal muscle PPARG in maintaining metabolic homeostasis. A study
published by Norris et al. demonstrated that muscle specific PPARG knockout mice develop
increased adiposity and insulin resistance138. Hevener et al. showed similar results, demonstrating
once again that muscle specific PPARG deletion causes insulin resistance and metabolic
dysfunction139. Additional evidence comes in the form of PPARG knockout from the adipose
tissue. He et al. showed that, in spite of the absence of PPARG in adipose tissue, TZD treatment
improved skeletal muscle insulin sensitivity140.
PPARG and Skeletal Muscle Metabolic Regulation in Breast Cancer
Our laboratory’s interest in the PPAR family of proteins arose from previous RNAsequencing analysis of muscle from breast cancer patients and BC-PDOX mice, which our group
found to recapitulate the clinical phenotype fatigue. Among the three PPAR isoforms, we identified
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PPARG as the key regulator in BC-induced muscle dysfunction. When comparing the
transcriptional signature of skeletal muscle in human breast cancer patients to skeletal muscle
from BC-PDOX mice, similar patterns emerged with respect to affected markers and pathways,
with 40 genes concordantly affected by breast tumor growth in skeletal from human breast cancer
patients and mice bearing human breast tumors124. This phenotype is largely characterized by
the down regulation of PPARG expression and concomitant decreases in many direct PPARG
target genes. A large percentage of differentially expressed genes common to both breast cancer
patients and BC-PDOX mice are either verified or predicted targets of PPARG. A subset of these
PPAR targets, including Cidec, Fabp4, Rbp4 and Slc1a5, are central to the network of proteinprotein interactions present in the skeletal muscle of both BC patients and BC-PDOX mice and
were validated and verified in both mouse and human muscle samples. Therefore, it is probable
that these genes and their associated networks represent a significant driving force behind breast
cancer-induced muscle dysfunction and fatigue and further suggests that PPAR signaling may be
mechanistically central to BC-associated skeletal muscle dysfunction.
PPARG Agonism as a Therapy for Breast Cancer-Induced Fatigue
We have consistently demonstrated that a systemic consequence of breast tumor growth
is the downregulation of PPARG in skeletal muscle67,124,126, and this phenotype can also be
induced by applying isolated BC- derived factors to skeletal muscle cells in vitro100. This
interaction results in the aberrant transcription of muscle mitochondrial genes and concomitant
mitochondrial dysfunction. PPARG as a therapeutic target has also been shown to rescue
mitochondrial dysfunction in a number of neurological disorders, including ALS144, and
Huntington’s disease145,146. In a model of Alzheimer’s disease, PPARG agonist treatment
increased mitochondrial biogenesis and improved glucose utilization145. Additionally rosiglitazone
treatment increased mitochondrial biogenesis, increased oxygen consumption, increased
mitochondrial mass, ΔΨm, mtDNA copy number, decreased autophagy and suppressed free
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radical generation in a model of Parkinson’s disease147. Pioglitazone also has a well-established
role in the treatment of type 2 diabetes, and has been shown to increase the expression of skeletal
muscle mitochondrial genes143, improve mitochondrial oxidative function148, and correct
dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis149. In support
of the mechanisms demonstrated in these previous studies, the current study demonstrates
therapeutically targeting PPARG in BC with pio is sufficient to restore muscle gene expression
patterns to that observed in muscles from non-tumor bearing control mice. This is particularly
evident through the restoration of the transcription of genes involved in pathways associated with
oxidative phosphorylation. This transcriptional restoration is accompanied by increased
mitochondrial ATP content and ATP synthase activity. Given the relationship between proper
skeletal muscle metabolic function and ATP generation, to the incidence of fatigue, and the role
of pio and other PPARG agonists in improving mitochondrial function in other diseases, we
suggest that pio be considered a promising candidate for the amelioration of fatigue in patients
with BC.
Cancer Cachexia and Metabolic Regulation in Breast Cancer
The major focus of this dissertation work is the characterization of systemic metabolic
changes in breast cancer that may contribute to the unique phenotypes of fatigue in the absence
of muscle wasting in many breast cancer patients. A secondary goal of this work is to highlight
this phenotype in the context of cancer cachexia, in an effort to bring about clinical recognition
and interventions for this condition. A discussion of cancer cachexia and the breast cancer
specific manifestations of this disease is thus warranted.
Cancer cachexia is a multifactorial syndrome that is characterized by the progressive loss
of adipose and skeletal muscle mass, systemic inflammation, and altered metabolic and energy
balance150. This phenotype cannot be fully reversed by conventional nutritional support and leads
to progressive functional impairment. This syndrome has a dramatic impact on patient quality of
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life and is also associated with poor responses to traditional tumor directed therapies such as
chemotherapy and radiation151–153. In cancer patients, cachexia is a major cause of morbidity and
mortality, with estimates predicting nearly 20% of all cancer related deaths are a direct result of
cachexia154,155.

Figure 1.4: Stages of cancer cachexia

The specific definitions and guidelines cancer cachexia were developed and described in
a seminal review from Fearon et al.150. The first point to recognize is that cancer cachexia is a
continuum, or spectrum condition, that consists of three stages, highlighted in Figure 1.4150. In
precachexia, early signs may include metabolic changes, anorexia, and impaired glucose
tolerance which precede substantial weight loss. By definition cachexia is characterized by
substantial weight loss, i.e. a patient who has lost more than 5% of stable body weight over the
past 6 months, or a body-mass index less than 20 kg/m 2 and ongoing weight loss of more than
2%, or sarcopenia and ongoing weight loss of more than 2%150. Patients with cachexia also often
have reduced food intake, and systemic inflammation. Finally, refractory cachexia is characterized
by a low performance status, non-responsiveness to anti-cancer treatment, and a life expectancy
of less than 3 months.
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While the Fearon guidelines use weight loss as the primary diagnostic indicator of
cachexia progression, an alternative set of guidelines has been presented by Evans et al.156.
While these guidelines still consider weight loss, additional factors proposed include decreased
muscle strength, fatigue, low fat-free mass index, and abnormal biochemistry Figure 1.5156.

Figure 1.5: Evans factors for the diagnosis and recognition of cancer cachexia.
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It is important to recognize that while these definitions are available, the underlying
mechanisms that cause this syndrome are not well understood, and these definitions are not
universally agreed upon. Even with these tool, the recognition and diagnosis of cachexia is still
relatively limited157–159. Attempts to establish a clinically meaningful definition have proven
challenging because of the focus on weight loss alone, and attempts to more comprehensively
define cachexia through body composition, physical functioning, and molecular biomarkers are
yet to be routinely incorporated into clinical practice159. Additional challenges include the fact that
there are currently no FDA approved therapies for the treatment of cancer cachexia, and the fact
that cancer cachexia presents at different rates and severities depending upon the type of cancer
present160,161. Breast cancer-associated cachexia is included in these challenges, as it presents
with a somewhat unique phenotype, but may be uniquely positioned to allow for the study of
tumor-induced mechanisms of cancer cachexia.
Cancer Cachexia in Breast Cancer
Breast-cancer associated cachexia provides a prime example of the difficulties involved
in applying the established guidelines for diagnosis and intervention. In breast cancer, fewer than
5% of patients meet the weight loss requirements needed to be diagnosed with cachexia, yet the
majority of these patients experience debilitating symptoms and aberrant metabolic regulation.
As we have discussed, breast cancer associated fatigue is perhaps the most common of these
consequences, with more than 90% of breast cancer patients experiencing moderate to severe
fatigue at some point during their disease48,162. This inevitably leads to a large, clinically significant
population that experiences debilitating physical impairments such as fatigue, reduced quality of
life, and reduced responsiveness to tumor-directed therapies, and lacks clinical interventions and
supportive therapies. Figure 1.6161 lists the relevant statistics for breast cancer associated
cachexia.
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While muscle strength and fatigue are strongly related to muscle mass in male cancer
patients, this does not appear to be the case in women. Studies in multiple cancer types indicate
female patients lose muscle quality without losing muscle mass163,164, therefore it is critical to
examine the mechanisms by which muscle wasting differs from muscle and metabolic dysfunction
in breast cancer, which is ultimately the major goal of this dissertation work.

Figure 1.6: Prevalence of cachexia and average% weight loss in various types of cancer.

Clinicians should be aware that a woman with breast cancer may be experiencing the symptoms
of cachexia, even when not presenting with frank weight loss-based cachexia.
Pathogenesis of Breast Cancer-Associated Fatigue and Metabolic Change
As breast cancer-associated fatigue and the mechanisms and consequences that underlie
it are the major focus of this work, we will now examine this in greater detail. Breast tumor growth
and associated signaling has the potential to induce fatigue at all of the levels previously
discussed while examining peripheral fatigue. It is now well-recognized that cancer cells and
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oncogenic signaling can have a profound effect on not only the tumor microenvironment, but also
systemically and within peripheral tissues.
The concept of the tumor macroenvironment has gained attention in recent years,
and examines how a tumor interacts with distant tissues and organs, and how metabolism
in these organs may be changes in response to tumor-derived factors. It is established
that tumors may cause systemic effects by releasing soluble factors into the blood or lymph
vessels165. The drive to sustain cellular proliferation is perhaps the main driver of this
process. The tumor first begins to model the surrounding environment, or
microenvironment, via autocrine and paracrine signaling, and chemokine release, which
among other things results in tumor directed angiogenesis166. The newly synthesized blood
vessels are able to contribute to the delivery of oxygen and nutrients to the tumor,
promoting growth, while simultaneously allowing the tumor to release a wide range of
factors into the bloodstream that may ultimately target many peripheral tissues.
In paraneoplastic conditions such as cancer cachexia, this connection between the
tumor and bloodstream may represent a key event that leads to the metabolic changes
described in peripheral tissue in our work and others. The metabolism of the tumor
macroenvironment may create the conditions that allow for the mobilization of
macronutrients, substrates, and other raw materials needed for the growth and
maintenance of the tumor. Evidence suggests that this comes at the expense of normal
metabolic control and homeostasis in target organs, such as the skeletal muscle167,168.
While the etiology of fatigue in breast cancer appears to be related to altered glucose, lipid,
and mitochondrial metabolism within the skeletal muscle, the mechanisms by which breast
tumor induce these changes remain unclear.
Potential Mechanisms for Breast Cancer-Induced Skeletal Muscle Dysfunction
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There are many tumor-derived factors that have the potential to induce the peripheral
phenotypes observed in breast cancer patients, and likely factors will be summarized here.
Inflammation and Cytokines
Cancer is characterized as an inflammatory disease38,151, and this inflammation is often
responsible for the metabolic alterations present in patients. Tumor cells may be one source of
this inflammation, through the direct release of cytokines and chemokines, while a second source
is activated immune cells which release many of the same factors169. Cytokines such as TNFalpha, IL-6, and interferon gamma, can promote the activation of transcription factors associated
with cachexia in both adipose and skeletal muscle tissue170,171. It has been well established that
cytokines secreted by host immune cells in response to tumors and/or by the tumor itself are
associated with muscle wasting and functional limitations172,173. Breast cancer patients who exhibit
fatigue have significantly higher serum levels of IL-1ra, sTNF-RII, and neopterin than non-fatigued
women174. NF-kB has been shown to increase the activity of the ubiquitin/proteasome pathway,
thereby accelerating the degradation of muscle proteins leading to muscle weakness175. More
recent research from Wang et al. showed that increased levels of TNF-alpha, TGF-beta, and Gcsf in plasma of PyMT+ mice were accompanied by lower muscle mitochondrial activity and
muscle dysfunction, which were restored upon inhibition of NF-kB signaling pathways176. TNFalpha and several other cytokines have been shown to decrease peripheral insulin sensitivity with
a mechanism that affects the activation of the insulin receptor and downstream signaling
molecules177. Collectively, these breast cancer-associated alterations in circulating cytokines
demonstrate the potential for cytokine driven tumor-associated muscle dysfunction.
Exosomes and their Roles in Disease
The role of tumor-derived extracellular vesicles in mediating cachexia is being increasingly
studied. Extracellular vesicles include exosomes and microvesicles, and are involved in cellular
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communication, immune response, tissue repair, epigenetic regulation, and in various diseases
including cancer169. Exosomes can act in autocrine, paracrine, and endocrine signaling, making
them potential mediators of the systemic changes observed in cancer cachexia associated
metabolic changes.
To briefly describe the biology of exosomes, they are a type of extracellular vesicle than
contains constituents from the cells that synthesize and secrete them. These constituents include
protein, DNA, RNA, lipid, metabolites, and miRNA178. Exosomes have a size range of
approximately 40nm to 160nm in diameter, and are endosomal in origin. Exosomes are generated
in a process that involves the invagination of the plasma membrane and the formation of
intracellular multivesicular bodies that are ultimately secreted as exosomes. These bodies can
then be further processed by the trans-Golgi network and the endoplasmic reticulum which
contribute to their formation and also the content of the exosome179.
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Figure 1.7: Biological functions of exosomes. https://www.science.org/doi/10.1126/science.aau6977

The focus of current exosomal research, and the focus of this review, are the questions
surrounding the functions of exosomes and their constituents and the phenotypic and molecular
alterations that they induce on recipient cells. The ability of exosomes to transfer genetic material
between cells has been confirmed in vivo using the Cre-Lox system as demonstrated by Riddler
et al180. In this study, it was demonstrated that intercellular transfer of functional Cre recombinase
mRNA from immune cells into neurons occurred in the absence of cell fusion. The immune cell
derived exosomal Cre mRNA was effectively able to induce expression of its floxed target gene
in neurons. Zomer et al. showed that Cre expressing malignant tumor cells release exosomes
that induce red-to-green Cre-dependent conversion in benign tumor cells, and that this in vivo
transfer occurs both locally and systemically181. This studies effectively demonstrate that
feasibility of intercellular and interorgan communication through exosomes, and opens the door
to examining the role exosomal communication plays in the etiology of various disease states.
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Exosomes have been shown to play a role in the emergence of metabolic diseases. They have
been found to transfer metabolites and facilitate intercellular communication through exosomal
miRNA exchange among pancreatic β-cells, adipose tissue, skeletal muscles, and the liver of
mice and humans182. Flow cytometric analyses have revealed a quantitative increase in circulating
exosomes in obesity and associated disease states including insulin resistance, diabetes, and
non-alcoholic fatty liver disease183–185. Dysfunction of white adipose tissue is considered a central
driver of metabolic disease and exosomes are secreted by primary adipocyte cultures, adipocyte
cell lines (e.g., 3T3-L1) and adipose tissue explants in vitro186. Studies performed in recent years
have investigated the roles of adipose-derived exosomes in the metabolic consequences of
obesity and adipose dysfunction. Several have reported that exosomes derived from obese
adipose tissue induce changes in lean target cells that are consistent with the obese
pheotype187,188. Mice fed a high fat diet display distinct exosomal miRNA profiles which are
sufficient to promote insulin resistance when injected in lean mice189. In a comparable study in
humans, adipose exosomes isolated from human white adipose tissue caused primary monocytes
to adopt properties characteristic of adipose tissue macrophages (ADMs), as defined by their
profile of pro- and anti-inflammatory gene expression and cytokine release188. The supernatant of
them ADM-like macrophages then impaired insulin signaling when applied to cultured adipocytes.
Exosomes in Breast Cancer and Cancer Cachexia
Exosomes are also implicated in the etiology of many cancers and much emerging
research has investigated the roles of exosomes in mediating oncogenic signaling mechanisms.
Exosomes have been implicated in the pathophysiology of breast cancer, and this section will
address the potential roles of tumor-derived exosomes in mediated cancer-cachexia.
Tumor cells exhibit enhanced exosome release for communication with both local and
distant cells. Exosomes are involved in all of the major hallmarks of cancer, including sustained
proliferation, angiogenesis, immune system evasion, genomic instability, apoptosis resistance,

38

deregulated cellular energetics, invasion and metastasis190,191. The mechanisms involved in
exosome driven regulation of these hallmarks in breast cancer have been extensively reviewed
by Lakshmi et al190. The roles of cancer-derived exosomes in mediating cancer cachexia have
been increasingly studied and recognized in recent years. Much of this research has focused on
the role of tumor-derived exosomal miRNA in mediating skeletal muscle atrophy. Miao et al.
demonstrated that exosomes secreted by colon cancer cells could decrease the diameter of
C2C12 myotubes in vitro and decrease mouse muscle strength and tibialis anterior muscle weight
in vivo192. They determined that several miRNA were expressed in greater abundance in the
exosomes of the cancer cells, and subsequently reproduced the previous results by using miRNA
mimics of the identified miRNA. In breast cancer, secreted exosomes have been shown to induce
catabolism of adipocytes and muscle cells through targeting of PPARG193. Once again, the results
of this study were mediated by miRNA, and specifically miRNA-155.
While much of the published research focuses mechanisms of cancer-induced muscle
wasting, we know that the mechanisms in breast cancer are potentially different, as we do not
see widespread atrophy in these patients. The hypothesis of this dissertation document posits
that breast cancer-derived exosomes are able to modulate metabolic and mitochondrial function
within the skeletal muscle, and there is evidence that exosomes are able to impact mitochondrial
function in various conditions. In a study from Nie et al. exosomal miRNA-194 was shown to cause
cardiac injury and mitochondrial dysfunction in obese mice194. When cardiomyocytes were
incubated with exosomes isolated from obese mice, mitochondrial complex activity was
significantly reduced, and this coincided with significantly reduced ATP content. We have
observed a similar phenotype in the skeletal muscle of breast cancer patients and BC-PDOX
mice100,125. While evidence of these exosome/miRNA induced phenotypes is accumulating, the
mechanisms remain poorly understood. One possibility is the ability of exosomal miRNA to
directly target proteins within the skeletal muscle resulting in the observed metabolic dysfunction.
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We have demonstrated evidence that one such target in breast cancer is skeletal muscle PPARG,
which is consistently down-regulated in skeletal muscle across all breast cancer subtypes125. The
miRNA mediated degradation of skeletal muscle PPARG in breast cancer, and subsequent
transcriptional changes remains an attractive hypothesis.
miRNA and PPARG
We have discussed miRNA at length already and will now briefly describe their biology
and mechanisms of action to contextualize their potential in mediating the regulation of skeletal
muscle PPARG in breast cancer. MicroRNAs are endogenous small noncoding RNAs of
approximately 16–22 nucleotides, which bind to complementary sequences (seed sequences) in
the 3′UTR of target mRNAs and mediate either their decay or translation inhibition195,196. Following
processing, the ultimate fate of miRNA is to be incorporated into a protein complex known as an
RNA induced silencing complex or RISC197. The mature miRNA RISC complex can then be
directed to complex with target mRNAs. miRNA-RISC mediated gene inhibition, is commonly
divided into three processes:(i) site-specific cleavage, (ii) enhanced mRNA degradation and (iii)
translational inhibition198. As we have not observed any differences in PPARG mRNA expression
in breast cancer, the posttranscriptional mechanisms of miRNA function are most likely to mediate
the phenotypes we see in our models.
The regulation of PPARG by miRNA has been studied in the context of cancer, and
metabolic disorders. Several studies have examined the role of miR-27 in PPARG regulation, and
have demonstrated that this miRNA targets PPARG resulting in decreased expression. A study
from Kin et al. revealed that miR-27a is involved in adipocyte differentiation by binding to the
PPARG 3'-UTR, resulting in downregulation of PPARG expression199. Lin et al. demonstrated
similar results, showing that the miR-27 gene family is downregulated during adipogenic
differentiation, and overexpression of miR-27 resulted in the inhibition of adipocyte formation200.
Studies in human hepatic stellate cells demonstrate that a variety of miRNAs are able to target
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and downregulate PPARG in a similar fashion, ultimately resulting in the development of cancer
progression201–203. In the study from Povero et al.202 hepatocyte derived exosomes released
during lipotoxicity were efficiently internalized by target human hepatic stellate cells resulting in
miRNA dependent suppression of PPARG. In triple negative breast cancer, miRNA-27b-3p has
been shown to promote tumor progression and metastasis through inhibition of PPARG204.
Despite these publications, there remains a general gap in knowledge concerning the
phenotypes observed in peripheral tissues exposed to breast tumors, and the mechanisms by
which breast cancer may induce them. The metabolic and mitochondrial dysfunction that we have
observed in skeletal muscle of breast cancer models is slowly being recognized for the potential
to contribute to the overall phenotype of breast cancer-induced fatigue. The work presented
herein is focused on characterizing these changes and applying therapeutic strategies in the form
of PPARG agonism with pioglitazone. Overall, the data support a mechanism by which breast
cancer-induced fatigue is associated with skeletal muscle mitochondrial dysfunction due to
dysregulated PPARG transcriptional networks, and pioglitazone supplementation represents a
promising therapeutic strategy for breast cancer patients.
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Chapter 3
Breast cancer-associated skeletal muscle mitochondrial function and lipid accumulation
is reversed by PPARG
Full Text Link: Am J Physiol Cell Physiol. 2021 Apr 1;320(4):C577-C590. doi:
10.1152/ajpcell.00264.2020. Epub 2021 Jan 13.

Breast Cancer-Associated Skeletal Muscle Mitochondrial
Dysfunction and Lipid Accumulation is Reversed by PPARG
This work expands upon our laboratories previous papers by transitioning to an in vitro
model system to identify metabolic alterations induced in skeletal muscle directly by BCderived factors and to determine whether the PPAR proteins are indeed involved in the
response. We show that BC cells secrete a factor that represses the transcriptional activity
of PPARs, induces downregulation of PPARG target genes, mitochondrial dysfunction,
and accumulation of lipid within differentiated muscle cells. The PPARG agonist drug
rosiglitazone was able to rescue BC-induced lipid accumulation but did not rescue the
effects of BC-derived factors on PPAR-mediated transcription or mitochondrial function,
but expression of exogenous PPARG protein reversed both BC-induced mitochondrial
dysfunction and lipid accumulation. Additionally, mitochondria exposed to breast cancer
conditioned media exhibit dysfunction in the form of impaired oxidative capacity, but
showed no differences in fatty acid oxidative function.
In this project I assisted in the molecular experiments, performed all of the requested
revisions and measurements of mitochondrial oxidative function and contributed to the
manuscript text.
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ABSTRACT
The peroxisome-proliferator activated receptors (PPARs) have been previously implicated in the
pathophysiology of skeletal muscle dysfunction in women with breast cancer (BC) and in animal
models of BC. This study investigated alterations induced in skeletal muscle by BC-derived
factors in an in vitro conditioned media (CM) system and tested the hypothesis that BC cells
secrete a factor that represses PPAR-gamma (PPARG) expression and its transcriptional
activity, leading to downregulation of PPARG target genes involved in mitochondrial function
and other metabolic pathways. We found that BC-derived factors repress PPAR-mediated
transcriptional activity without altering protein expression of PPARG. Further, we show that BCderived factors induce significant alterations in skeletal muscle mitochondrial function and lipid
accumulation, which are rescued with exogenous expression of PPARG. The PPARG agonist
drug rosiglitazone was able to rescue BC-induced lipid accumulation, but did not rescue effects
of BC-derived factors on PPAR-mediated transcription or mitochondrial function. These data
suggest that BC-derived factors alter lipid accumulation and mitochondrial function via different
mechanisms that are both related to PPARG signaling, with mitochondrial dysfunction likely
being altered via repression of PPAR-mediated transcription, and lipid accumulation being
altered via transcription-independent functions of PPARG.
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INTRODUCTION
Breast cancer (BC)-associated skeletal muscle fatigue is a chronic problem among BC
survivors, being reported by a majority of patients both prior to and after receiving anti-cancer
therapies (1-5). Recent studies show that deficits in muscle function predict shorter survival in
cancer, perhaps due to the fact that fatigue is known to reduce a patient’s tolerance to anticancer therapies (3,6-10). Therefore, improving muscle function in BC patients has the potential
to improve both quality of life and survival in the most commonly diagnosed cancer type in
women.
The syndrome of cancer-associated cachexia, where individuals with cancer lose a
significant portion of their bodyweight and also experience a decline in physical function (11,12),
has gained increasing attention in recent years (13). While most agree that for a person to be
cachectic, they must exhibit a significant degree of weight loss (11,12,14), it is now generally
accepted that cachexia is a process that progresses through distinct stages, including: 1) precachexia, where individuals have not lost significant bodyweight but experience other cachexiarelated symptoms; 2) cachexia, where patients have lost 5% or more of their pre-diagnosis
body weight; and 3) refractory cachexia (12). Improvements in muscle function could be of
substantial benefit to patients at any stage along this continuum. In pre-cachexia and cachexia,
improving muscle function could allow patients to complete anti-cancer treatment regimens
and/or physical therapies aimed at preventing cachexia progression, and in refractory cachexia,
improvements in muscle function would represent a welcomed quality of life benefit to many
patients.
The peroxisome-proliferator activated receptors (PPARs) are lipid sensing, ligand
activated transcription factors previously implicated in a variety of pathologies, including cancer,
atherosclerosis, Alzheimer’s disease, type 2 diabetes mellitus, and others (15-18). These
transcription factors aid in regulating whole body energy homeostasis via regulation of genes
involved in lipid metabolism and mitochondrial functions (15,19-23). Recently, downregulation of

45

PPAR-gamma’s (PPARG) transcriptional activity in skeletal muscle has been identified as a
potential central regulator of the increased muscle fatigue experienced by women with BC and
is recapitulated in the patient-derived orthotopic xenograft model of BC (24,25). However, the
mechanism by which PPARG downregulation induces muscle dysfunction has not yet been
explored. In the current study, we utilized conditioned media (CM) from murine breast tumor
cells lines representing the luminal and Her2/neu+ BC subtypes to test the hypothesis BC cells
secrete a factor that represses PPARG expression and its transcriptional activity, leading to
downregulation of PPARG target genes involved in mitochondrial function and other metabolic
pathways. The experimental data we present support a mechanism whereby breast tumor
secreted factors directly interact with skeletal muscle cells to induce mitochondrial dysfunction
and lipid accumulation through both transcriptional-dependent and independent activity of
PPARG.
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RESULTS
BC-CM represses PPARG expression and PPAR-mediated transcription
Because PPARG is downregulated in the skeletal muscle of women with BC and in mouse
models of BC (24), we first investigated the capacity of BC-derived factors to downregulate
Pparg mRNA expression in an in vitro model system. To test this, we collected CM from BC or
control cell lines and applied this CM to differentiated skeletal muscle cells in culture (Figure
1A). Cells and large debris were removed from the media via gentle centrifugation and
decanting, and the conditioned media was diluted 1:3 in fresh growth media to correct pH and
overall nutrient content. Importantly, all CM was applied to myotubes within 2 hours of collection
to ensure that biologically active components would not degrade or be damaged by freezing
prior to application. Using this model system, we found that CM from BC cell lines significantly
downregulated Pparg mRNA expression (Figure 1B) and several of its purported transcriptional
targets (26) in differentiated skeletal muscle after as little as two hours of CM exposure,
compared to media conditioned by skeletal muscle myoblasts (Figure 1C). However, no
significant change in PPARG protein expression was detected (Figure 1D), suggesting that the
downregulation of PPARG target genes’ mRNA is due to a repression of PPAR-mediated
transcriptional activity, rather than a downregulation of PPARG protein abundance. To directly
address this discrepancy, we generated an HEK reporter cell line stably expressing a PPARresponsive reporter construct driving expression of GFP. Using this system, we have
consistently observed a significant reduction in GFP intensity in response to BC-CM. In contrast,
CM from a non-tumorigenic mammary epithelial cell line does not repress GFP expression
(Figure 1E).

BC-CM induces mitochondrial dysfunction and lipid accumulation in myotubes
We next asked whether BC-CM induced functional alterations in differentiated muscle cells that
could be reflective of the increased muscle fatigability seen in women with BC and BC animal
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models. We found that BC-CM induced substantial changes in aerobic metabolism, specifically
leading to a repeatable reduction in oxygen consumed in ATP generation, while oxygen
consumed in ATP generation was unchanged by the normal mammary epithelial cell line EpH4EV (Figure 2A). Other parameters of mitochondrial function, including alterations of basal
respiration, maximal respiration, and proton leak were not consistently replicated across 5
individual experiments, as assessed in myotubes. CM from the luminal EO771 BC cell line
repressed aerobic metabolism without altering glycolytic function, while the HER2overexpressing NF639 line repressed both aerobic metabolism and glycolytic functions (Figure
2B). This reduction in aerobic metabolism does not appear to be related to mitochondrial
biogenesis, as suggested by the lack of alteration in mitochondrial DNA copy number in CMtreated myotubes (Figure 2C).
Because lipotoxicity-induced mitochondrial dysfunction has been reported in various
clinical contexts (27-30), and because individuals with cancer have been shown to have
increased lipid content in muscle (31,32), we assessed intramyocellular lipid concentration in
response to BC-CM using oil red o staining and automated image quantification. Using this
methodology, we repeatedly observed a significant increase in intramyocellular lipid staining
with EO771-CM, but in no experiment did we observe an increase in response to NF639-CM
(Figures 2D – 2E). In addition to the quantifiable increase in lipid content, EO771 CM also
appeared to alter lipid localization. Rather than being relatively evenly distributed across the
cell, the lipid in C2C12s treated with EO771 CM shifts to a more punctate distribution, perhaps
due to concentration in lipid droplets. The potential contribution of greater lipid accumulation on
mitochondrial function was analyzed by isolating mitochondria from myotubes after exposure to
BC-CM and performing a mitochondrial stress test using palmitate as the substrate to determine
fatty acid oxidation. Several functional parameters were assessed; however, there were no
significant differences observed in any of the groups that were assessed (supp Fig 1).
Diameter of C2C12 myotubes exposed to either EO771 or C2C12 CM was not different,
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suggesting the observed alterations in mitochondrial function are independent of myotube
atrophy (supp. Fig 2).

BC-CM decreases mitochondrial respiration and electron flow through mitochondrial
electron transport chain (ETC) complexes.
To evaluate overall mitochondrial function and health in this in vitro system, we performed
mitochondrial stress assays in isolated mitochondria from C2C12 myotubes exposed to BC-CM
to assess State 3 and 4 respiration as well as electron flow through the mitochondrial ETC
complexes. State 3 respiration was significantly lower in isolated mitochondria following
exposure to both E0771 and NF639 CM; non-mitochondrial respiration was not affected (Figure
3A). Both E0771 and NF639 CM also negatively affected electron flow through the
mitochondrial ETC complex I, while NF639 CM negatively affected electron flow through ETC
complex 2 and 4 (Figure 3B). These data in isolated mitochondria provide support of our data in
skeletal myotubes exposed to BC-CM and suggest a direct effect of a factor or factors in BC-CM
on mitochondrial function in skeletal muscle.

Exogenous PPARG expression rescues BC-CM-induced mitochondrial dysfunction and
lipid accumulation
To determine whether or not the alterations induced in skeletal muscle by BC-derived factors
are regulated by PPARG, we first attempted to generate stable myogenic cell lines expressing
exogenous PPARG constructs or shRNA against PPARG using lentiviral infection and
subsequent selection. Consistent with previous reports (33), genetic modification of PPARG in
C2C12 myoblasts resulted in cell lines that rapidly lost differentiation competence, within five
passages from lentiviral infection. Despite these limitations, early passage cells expressing
exogenous PPARG (Figure 4A) were used to ascertain whether PPARG is involved in the
response of myotubes to BC-derived factors. In these experiments, it was found that cells
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expressing exogenous PPARG were resistant to both BC-CM-induced repression of aerobic
ATP generation (Figure 4B) as well as BC-CM-induced lipid accumulation (Figures 4C – 4D).
Cells stably expressing shRNA against PPARG lost differentiation capacity immediately after
lentiviral infection and could therefore not be used to determine if PPARG ablation phenocopies
the effect of BC-CM in the context of differentiated muscle cells.

PPARG agonist rosiglitazone rescues BC-CM-induced lipid accumulation but fails to
rescue BC-CM-induced mitochondrial dysfunction and PPAR repression
Finally, we pharmacologically targeted PPARG to overcome BC-induced mitochondrial
dysfunction and lipid accumulation, using the potent PPARG agonist rosiglitazone (rosi) of the
thiazolidinedione (TZD) drug class. Rosiglitazone did induce PPAR-mediated transcription in the
absence of BC-CM (Figure 5A), but it was unable to rescue BC-CM’s repression of PPARmediated transcription (Figure 5B). Unsurprisingly then, this agonist did not rescue BC-induced
repression of aerobic ATP production (Figure 5C). However, rosiglitazone did potently repress
BC-induced lipid accumulation (Figure 5D). These data indicate that the mechanism by which
rosiglitazone prevents BC-induced lipid accumulation is independent of PPARG’s transcriptional
activity, and that BC-induced lipid accumulation is not the cause of BC-induced mitochondrial
dysfunction in this model system.
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DISCUSSION
In the present study, we have identified that BC-derived factors can significantly alter
mitochondrial function and PPAR activity in skeletal muscle cells without the involvement of
immune or stromal cell mediators, indicating that BC cells secrete a factor that induces these
effects by interacting directly with skeletal muscle. Numerous publications have characterized
changes in serum contents of women with BC, including changes in miRNAs, lipids, and
proteins (34-38), though the exact sources of many of these factors remain unknown. To our
knowledge, this report is the first showing that BC-CM induces alterations in skeletal muscle
mitochondrial function, with previous studies focusing on BC-CM’s effect on immune cells,
fibroblasts, endothelial cells, or normal mammary epithelium (39-44), or on transcriptional
changes induced in skeletal muscle (45). Although speculative, these in vitro data suggest that
molecular and functional alterations in skeletal muscles are the result of tumor-specific factors
that are secreted into the circulation and affect skeletal muscles, and are not necessarily linked
to systemic changes in inflammation, nutritional or metabolic disturbances or side effects of
treatments.

It is well established that BC cells can regulate both local and systemic immune
functions (46,47), and that inflammatory signaling is intrinsically linked to cancer-associated
skeletal muscle wasting (12,48). Thus, a reasonable assumption is that BC’s influence on
immune cells is the cause of BC-induced skeletal muscle fatigue. This study contradicts this
assumption by showing that no immunological mediators are required for BC cells to induce
significant alterations in skeletal muscle metabolic function. This study also contradicts recent
reports of negative results in other cancer types, where CM from cancer cells was unable to
directly induce mitochondrial deficits in differentiated skeletal muscle (49), indicating that
different cancer types induce skeletal muscle dysfunction via different mechanisms. While we
cannot conclusively state that mitochondrial dysfunction or lipotoxicity are the root causes of
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BC-induced skeletal muscle dysfunction, it is reasonable to hypothesize a causal link that
should be further investigated. Most likely, there are numerous mechanisms contributing to
skeletal muscle dysfunction that would need to be simultaneously targeted to provide symptom
control.

The mechanism by which BC cells induce mitochondrial dysfunction in this model
system appears to be related to signaling by the PPAR proteins, as evidenced by the rescue of
mitochondrial dysfunction and lipid content provided by exogenous expression of PPARG. This
finding provides support for the translational relevance of this in vitro model system, as PPARG
has been previously identified as a potential key regulator of BC-induced skeletal muscle fatigue
using both human data and data generated in the patient-derived orthotopic xenograft model of
BC (24,25,50). Additionally, this finding illuminates potential therapeutic modalities using the
numerous FDA-approved agents that target the PPAR proteins, including drugs with various
specificities for the three PPAR isoforms. In support of this possibility, we show here that the
PPARG-specific agonist rosiglitazone completely reversed BC-CM’s effect on skeletal muscle
lipid accumulation. Interestingly, this result does not appear to be due to rosiglitazone activating
PPAR-mediated transcription, suggesting that the effect is mediated by non-canonical functions
of PPARG.

While we were unable to rescue BC-induced mitochondrial dysfunction using
rosiglitazone, it is possible that pharmacological agents targeting PPAR-alpha, PPAR-delta, or a
combination of the three isoforms could overcome these effects of BC-derived factors (51).
Alternatively, it is possible that the mitochondrial dysfunction induced by BC-CM is due to
alteration of ligand-independent functions of PPARG, which would be overcome by the addition
of PPARG protein but not by exogenous ligand. Numerous reports confirm the ability of PPARG
to function as a transcription factor in the absence of ligand binding (52-55), and there is
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evidence of PPARG having ligand-independent functions that are also independent of its
transactivation domain (56). Pharmacological strategies to target these unique functions could
include non-TZD insulin-sensitizing agents or epigenetic modifiers.

Mechanistically, muscle fatigue can result from a myriad of factors, but the underlying
ability of the contractile elements to maintain force production relies upon the muscle’s ability to
resynthesize ATP following stimulus. We have observed dysregulation of metabolically significant
PPAR transcriptional networks in the skeletal muscle of BC-PDOX mice (24), as well as a
significant reduction in ATP from mitochondria isolated from skeletal muscle of these mice (24).
In support of these murine observations, proteomics analysis in the skeletal muscle of HER2+ BC
patients revealed lower protein expression of nearly every component of the mitochondrial ETC
and a correspondingly lower ATP content in muscle biopsies from BC-patients of multiple tumor
subtypes (25). These data clearly demonstrate mitochondrial dysfunction in muscle of patients
with BC, which will directly impact the fatigability of skeletal muscle. The results presented herein
expand on our previous studies and suggest this mitochondrial dysfunction is a direct result of
BC-derived factors. Intriguingly, we demonstrate that this mitochondrial dysfunction is
accompanied by increased intracellular lipid deposition in myotubes exposed to BC-CM.
Intramuscular lipid deposition has also been observed in type 2 diabetes (57) and smokinginduced insulin resistance (58). As the downregulation of PPARG expression and transcriptional
activity is associated with the development of insulin resistance (59) and many PPAR
transcriptional targets are mitochondrial lipid transport proteins (26), we hypothesized that a
decreased capacity for mitochondrial lipid import may contribute to the observed phenotype of
BC-induced lipid accumulation, which may then contribute to insulin resistance. However, this
lipid accumulation does not appear to be due to decreased rates of fatty acid oxidation in cells
exposed to BC-CM, as assessed by palmitate stimulated mitochondrial stress assays. This result
was somewhat unexpected, and future studies should aim to further elucidate the mechanisms of
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this lipid accumulation. Finally, aberrant intramyocellular lipid deposition can in many cases
contribute to lipotoxicity characterized by the accumulation of toxic lipid intermediates such as
diacylglycerols and ceramides (60), increased production of ROS (61), and is associated with
changes in autophagic dynamics (62,63), all of which are implicated in reduced mitochondrial
function within skeletal muscle. The sum of these observations suggests that skeletal muscle
lipotoxicity in breast cancer could play a major role in the phenotype of BC induced skeletal
muscle fatigue independent of mitochondrial dysfunction, and future studies should investigate
this potential link in greater detail.

In summary, our results confirm the ability of BC-derived factors to directly alter
metabolic function in skeletal muscle cells without the involvement of other cell types. These
BC-CM-induced phenotypes in skeletal muscle could be enacted by a variety of secreted
factors, including miRNAs, exosomes, or proteins, and appears to be mediated via signaling of
the PPAR proteins, though perhaps not through their canonical functions as ligand-activated
transcription factors. Specifically, BC-derived factors have the ability to repress the
transcriptional activity of PPARG, and this effect is not due to downregulation of PPARG protein
abundance. Additionally, repression of PPARG transcriptional activity induces mitochondrial
dysfunction in muscle cells and a deficiency in ATP supply while also being associated with
greater lipid accumulation. While PPARG protein levels are not affected in our model, basal
protein expression of PPARG is relatively low in skeletal muscle, providing an explanation for
the ability of exogenous PPARG to rescue these phenotypes while PPARG-agonists do not
(Figure 6). These results provide support for previous publications implicating the PPAR
proteins in BC-induced skeletal muscle fatigue and provide rationale for investigating PPAR
agonists to improve quality of life in survivors of BC (24,50).
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EXPERIMENTAL PROCEDURES
Cell culture. Cell lines utilized include EpH4-EV (immortalized normal murine mammary
epithelium), EO771 (murine luminal BC), NF639 (murine HER2/neu-overexpressing BC),
HEK293 (human embryonic kidney), and C2C12 (murine myoblasts). All cell lines were obtained
from ATCC (Virginia, USA), with the exception of EO771, which were obtained from Dr.
Metheny-Barlow at Wake Forest University. All cell lines were cultured in DMEM (Thermo
Fisher, Massachusetts, USA) supplemented with 10% heat inactivated fetal bovine serum
(Atlanta Biologicals, Georgia, USA) and penicillin/streptomycin (Thermo Fisher) at 37oC with 6%
CO2.

Exogenous PPARG myogenic cell line. Lentiviral particles containing pLenti-C-PPARG2mGFP-P2A-Puro or pLenti -mGFP-P2A-Puro were purchased from Origene (Maryland, USA).
Titers were provided by the manufacturer. C2C12 cells were plated at 125,000 cells per well in
24-well plates and infected with a multiplicity of infection of 75 transforming units per cell with 8
µg · mL-1 polybrene in antibiotic-free DMEM. Media was changed 20 hours after infection.
Starting 48 hours after infection, cells were cultured in 2 µg · mL-1 puromycin for 10 days, after
which cells were maintained in 0.5 µg · mL-1 puromycin indefinitely. Uninfected control cells
exhibited 100% death within 3 days of puromycin selection. Second passage cells were used in
Western blotting analysis to assess expression of PPARG2 protein. All experiments with these
cell lines were conducted within 5 passages of lentiviral infection as higher passage cells lost
differentiation competence.

Conditioned media (CM) collection. CM donor cells were plated at approximately 15%
confluence in separate 10cm dishes for 48 hours. The 48-hour CM was then removed from all
cell lines using a serological pipette, centrifuged at 1,500 RPM for 10 minutes, and the
supernatants were collected via decanting into new centrifuge tubes. The collected CM was
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then diluted 1:3 in fresh growth media prior to application to recipient cells. CM was always
applied to recipient cells within 2 hours of collection, in most cases within 15 minutes of
collection (Figure 1A). In some experiments, rosiglitazone (Millipore-Sigma, Massachusetts,
USA) in dimethyl sulfoxide (DMSO) was added to the diluted conditioned media to final
concentrations of 10 µM rosiglitazone and 0.1% DMSO prior to CM application to donor cells. In
experiments where rosiglitazone was used, DMSO was added to control CM to 0.1% final
concentration as a vehicle control.

Western blotting. Differentiated C2C12s were lysed in 50 mM Tris-HCl (pH 6.8) with 2%
sodium dodecyl sulfate and heated to 100oC for 3 cycles of 3 minutes each with vortexing and
brief centrifugation between heating cycles. Lysates were diluted to a final concentration of 1 µg .
µL-1 in NuPAGE LDS Sample Buffer (ThermoFisher Scientific) and 5% β-mercaptoethanol. 12
µg of total protein was loaded per well and resolved in NuPAGE Novex 4-12% Bis-Tris Gels
(ThermoFisher Scientific). Proteins were transferred to nitrocellulose membrane, blocked for 1
hour in 1X tris-buffered saline (TBS), 0.1% Tween20, 5% milk followed by incubation with
primary antibody overnight at 4°C in TBS-tween20 with 5% milk. Membranes were then washed
3 times in TBS + 0.1% Tween20 prior to application of appropriate secondary antibody
(ThermoFisher Scientific) for 90 minutes at room temperature, and again prior to application of
Pierce ECL Western Blotting Substrate (ThermoFisher Scientific). Relative band intensity was
quantified using the GE Amersham Imager 600 (GE Healthcare Life Sciences, Marlborough,
MA, USA) and normalized to GAPDH. Primary antibodies included PPARγ (#PA3-821A) and
GAPDH (#2118S).

BC-CM metabolic analyses in C2C12 myotubes. C2C12 cells were plated into Agilent
Seahorse XF96 or XF24 (Agilent Technologies, California, USA) plates at 10,000 cells. well-1
and differentiated in 2% horse serum (Atlanta Biologicals) in DMEM with antibiotics for 48 hours.
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Meanwhile, EpH4-EV, EO771, NF639, and C2C12 cells were plated at approximately 15%
confluence in separate 10cm dishes for 48 hours. 48-hour CM, prepared as described above,
was then applied to the 2-day differentiated C2C12 cells in Seahorse assay plates for 48 hours
(n=6-12 wells per treatment condition, noted in figure legends) prior to conducting the Agilent
Seahorse XF Cell Mito Stress Test, Agilent Seahorse XF Glycolysis Stress Test, or Agilent XF
Long-Chain Fatty Acid Stress Test protocols according to manufacturer’s instructions (sample
sizes for each experiment are identified in Figure Legends). For the Mito Stress Test, substrate
(Seahorse XF DMEM with 1mM pyruvate, 2mM glutamine, and 10mM glucose) was added prior
to running the assay. Injections in final concentrations were as follows: 1) Oligomycin (1uM); 2)
FCCP (0.5uM); 3) Rotenone/Antimycin-A (1uM). For the Long-Chain Fatty Acid Stress Test
substrate was prepared by adding BSA-Conjugated Palmitate (5mM) to Seahorse XF Substrate
Limited Media. Injections were performed as in the Mito Stress Test. For the Glycolysis Stress
Test, substrate was prepared by adding 2mM glutamine to Seahorse XF Base Medium.
Injections were as follows: 1) Glucose (10mM); 2) Oligomycin (1uM); 3) 2DG (50mM). For the
ATP Coupling Assay, substrate (final concentration of 10mM pyruvate + 1mM malate) was
added and incubated in a non-CO2 incubator at 37ͦ C for 10 min before being placed in the
instrument. Injections in final concentrations were as follows: 1) ADP (4uM); 2) Oligomycin
(4mM); 3) FCCP (4uM); and 4) Rotenone (4uM) + Antimycin-A (4uM). For the Electron Flow
assay, substrate (final concentration of 10mM pyruvate + 1mM malate) was added and
incubated in a non-CO2 incubator at 37ͦ C for 10 min before being placed in the instrument.
Injections in final concentrations were as follows: 1) Rotenone (2uM); 2) Succinate (10mM); 3)
Antimycin-A (4uM); and 4) Ascorbate (10mM) + TMPD (1mM). The mix, wait, measure cycle
was 30 seconds, 30 seconds, and 2 minutes. Two cycles were performed before the first
injection, and 2 cycles were performed following each injection. Data were normalized as
described previously. Oxygen consumption and/or extracellular acidification rates were
normalized to account for inter- and intra-plate variability, resulting in each individual well’s first
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measurement representing 100%. Subsequent to this normalization, individual parameters of
aerobic and glycolytic metabolism were calculated according to manufacturer’s instructions.

Analyses of BC-CM on isolated mitochondria from C2C12 myotubes. C2C12 myoblasts
were plated at approximately 15% confluency in 10cm2 culture plates, and induced to
differentiate using 2% HS. 48-hour CM from EO771 and NF639 cells was applied to 2-day
differentiated C2C12 myotubes for 48 hours. Following CM exposure, C2C12 myotubes were
collected, and mitochondria were then isolated using the Mammalian Mitochondria Isolation Kit
For Tissue & Cultured Cells (BioVision, Cat# K288), according to the manufacturer’s protocol.
Isolated mitochondria were suspended in mitochondrial assay solution (MAS) and the Bradford
protein assay was performed to quantify protein content. Mitochondrial function and health
were subsequently assessed with ATP Coupling and Electron Flow assays, which were
performed in the Agilent Seahorse Bioanalyzer per the manufacturer’s instructions using
10ug/well. Three biological replicates were run for each cell line being examined, and three
technical replicates were run for each biological replicate. This experiment was performed in
duplicate plates to account for inter and intra-plate variability. The OCR values for each time
point of the technical replicates for each biological replicate were averaged and used to derive
the mitochondrial respiratory parameter data for each biological replicate. Raw OCR data was
normalized to offset instrument error by setting the most negative value from all successful wells
in the data set to 0. State 2 respiration was taken by the highest OCR value of the two time
points before the first injection, State 3 respiration was taken by the highest OCR value of the
two time points immediately after the injection of ADP, State 4o respiration was taken by the
lowest OCR value of the two time points immediately after the injection of oligomycin, State 3u
respiration was taken by the highest OCR value of the two time points immediately after the
injection of FCCP, and non-mitochondrial respiration was taken by the lowest OCR value of the
two time points immediately after the injection of rotenone + antimycin-A. For the ATP Coupling
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Assay, injections in final concentrations were as follows: 1) ADP (4uM); 2) Oligomycin (4mM); 3)
FCCP (4uM); and 4) Rotenone (4uM) + Antimycin-A (4uM). For the Electron Flow assay,
injections in final concentrations were as follows: 1) Rotenone (2uM); 2) Succinate (10mM); 3)
Antimycin-A (4uM); and 4) Ascorbate (10mM) + TMPD (1mM). The mix, wait, measure cycle
was 30 seconds, 30 seconds, and 2 minutes. Two cycles were performed before the first
injection, and 2 cycles were performed following each injection. Data were normalized as
described previously.

PPAR-reporter assays. HEK293 cells were transfected with PPRE-H2b-eGFP (64)
(Addgene #84393) using Invitrogen Lipofectamine 3000 (Thermo Fisher), selected with 500
ng·uL-1 Gibco geneticin (Thermo Fisher) for 20 days, and flow-sorted to select the cells
expressing GFP. The resulting HEK293-PPRE-H2b-eGFP cell line was plated at approximately
15% confluence in a 24-well plate. The following day, cells were imaged using the BioTek
Cytation 5 Cell Imaging Multi-Mode Reader (Agilent Technologies) to collect baseline GFP
intensity, and 72-hour conditioned media from HEK293, EpH4-EV, EO771, and NF639 cell lines
was applied to the 24-well plate, using individual wells as biological replicates (n=6 wells per
treatment condition). CM donor cells were plated on D0 as described above, and HEK-PGFP
cells were plated at approximately 15% confluence on Day 1 (D1). On D2, baseline GFP
intensity was collected using the BioTek Cytation 5 Cell Imaging Multi-Mode Reader (Agilent
Technologies), and subsequently 48-hour conditioned media from HEK293, EpH4-EV, EO771,
and NF639 cell lines was applied to the 24-well plate (n=3-6 wells per treatment condition,
noted in figure legends). HEK-PGFP cells were then incubated in CM under normal culture
conditions and GFP intensity was quantified 24 hours later using identical imaging settings as
the baseline measurements. Mean GFP intensity per well was calculated using Gen5 Microplate
Reader and Imager Software (Agilent Technologies), obtaining a single value per well that
represented the mean GFP intensity of all cells in the imaging field for that well.
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qRT-PCR for PPAR target genes. C2C12 cells were plated at approximately 90% confluence
in 24-well plates (150,000 cells/well) on D0 and differentiated in 2% horse serum (Atlanta
Biologicals) in DMEM with antibiotics. On D3, differentiation media was refreshed on the
C2C12s, and CM donor cells were plated as described under “CM collection.” On D4, media on
the differentiating C2C12s was changed back to normal growth media (10% FBS in DMEM with
antibiotics). On D5, CM was collected and applied to the differentiated C2C12 cells for 2 or 24
hours, with n=3-8 wells per condition, as noted in figure legends. Total RNA was isolated from
CM- and/or drug-treated cells using Trizol (ThermoFischer Scientific, Waltham, MA, USA) and
established methods (65). 1200 µg of cDNA was produced using Invitrogen SuperScript III FirstStrand Synthesis System (ThermoFisher Scientific) according to manufacturer’s protocol, and
relative expression of selected genes was analyzed using SYBR Green PCR Master Mix
(ThermoFisher Scientific) with the Applied Biosystems QuantStudio 6 Flex (ThermoFisher
Scientific), using 60 ng cDNA per reaction. Primer efficiencies were determined to be between
85% and 115% and relative mRNA expression was calculated using the Pfaffl method (66)
normalized to 18s rRNA. Primer3 was used to design qRT-PCR primers (Supplementary Table
1) (67).

qRT-PCR for mitochondrial DNA. C2C12 cells were plated at approximately 90% confluence
in 24-well plates (100,000 cells.well-1) on D0 and differentiated in 2% horse serum in Gibco
DMEM with antibiotics. Differentiation and CM application was conducted as described under
“qRT-PCR for PPAR target genes,” with CM applied for 24 hours and n=8 wells per condition.
Total DNA was isolated from CM-treated cells using the DNeasy Blood & Tissue Kit (Qiagen,
Hilden, Germany) according to manufacturer’s instructions. 40-60 ng of DNA in 1uL eluting
buffer was used for qRT-PCR using Applied Biosystemcs TaqMan Universal PCR Master Mix
(ThermoFisher Scientific) with the Applied Biosystems QuantStudio 6 Flex (ThermoFisher
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Scientific). Primer-probe sets were purchased from ThermoFisher Scientific (Applied
Biosystems Gene Expression Assays, COX2 Mm03294838_g1 and 18S Mm03928990_g1).
Relative COX2 mtDNA was quantified using the ΔΔCT method normalized to 18S gDNA.

Oil red O. C2C12 cells were plated at approximately 90% confluence in 24-well plates (100,000
cells.well-1) on D0 and differentiated in 2% horse serum in Gibco DMEM with antibiotics. On D2,
differentiation media was refreshed on the C2C12s, and CM donor plates were set up as
described under “CM collection.” On D4, CM was collected and applied to differentiated C2C12s,
and CM donor cells were split to allow for CM to be collected once more after 48 hours
incubation. On D6, CM was again collected and was used to refresh the CM on the recipient
cells. On D7, cells were fixed in 4% formaldehyde for 30 minutes, washed 3 times in distilled
water, and made permeable with 60% isopropanol for 10 minutes. Oil red o stock solution had
been previously suspended in 100% isopropanol and filtered using a 0.2 µm bottle-top filter. Oil
red o stock solution was diluted to 60% in distilled water to create the working solution. Working
solution was applied to the fixed and permeable cells for 10 minutes. Cells were washed 3x with
distilled water and stored at 4oC until imaging, typically within 24 hours of staining. Images were
taken using a Zeiss Axiovert 40 CFL microscope with a Zeiss Axiocam 105 color camera,
running ZEN 2.3 software. Effort was made to take images at the center of each well to produce
even illumination across images. All images within each experiment were taken using identical
imaging settings. Images were analyzed using the countcolors package version 0.9.1 (68) in R
version 3.6.1 (69), quantifying the area of each image within a 50% radius from true red.

Assessment of Myotube Diameter. To assess myotube diameter, the diameter of every
myotube per field was manually measured at its widest width using the measure function of the
ImageJ ROI manager (National Institutes of Health, Bethesda, Maryland) and myotube diameter
distributions for each experimental condition were constructed. These measurements were
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performed on the images used for the oil red O staining described previously, resulting in
measurements being performed at day 7 of myotube differentiation.

Statistical analyses, reproducibility, and rigor. Data analyses were conducted in R version
3.6.1 (69) using ggpubr version 0.2.4 (70) for data visualization and statistical tests. Unless
otherwise stated, all statistical tests used were unpaired, two-tailed t-tests for two-group
comparisons, one-way ANOVA for multi-group comparisons, and two-way ANOVA for
comparisons involving two variables. When multiple comparisons were used within an
experiment, Holm-Bonferroni correction was applied to adjust p-values. Graphs represent data
from a single, independent experiment. All experiments have been repeated at least twice with
similar results, with most experiments being repeated more than 3 times. All cases where
inconsistent results were obtained across repeated experiments are explicitly stated in the text.
For all box and whisker plots: the total height of the box represents the interquartile range (IQR),
the thick center line represents the median value, and the whiskers extend to the most extreme
data point that is not an outlier, with an outlier being defined as a value more extreme than 1.5 x
IQR. Outlier values are represented by a single dot beyond the whiskers.
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FOOTNOTES
1

Wilson, H.E., Stanton D.A., Montgomery, C., Infante, A.M., Taylor, M., Hazard-Jenkins, H.,

Pugacheva, E.N., and Pistilli, E.E. (2019) Skeletal muscle reprogramming by breast cancer
regardless of treatment history or tumor molecular subtype. BioRxiv,
doi: https://doi.org/10.1101/810952.
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ABBREVIATIONS
Breast cancer (BC), conditioned media (CM), peroxisome-proliferator activated receptor
(PPAR), peroxisome-proliferator activated receptor gamma (PPARG), rosiglitazone (rosi), trisbuffered saline (TBS), thiazolidinedione (TZD)
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TABLES
Supplementary Table 1: Primers used for qRT-PCR
Forward Primer

Reverse Primer

18s

5’-AATGCTTTCGCTCTGGTCCG

5’-CCTGGATACCGCAGCTAGGA

Cidec

5’-AGCTAGCCCTTTCCCAGAAG

5’-CCTTGTAGCAGTGCAGGTCA

Fabp4

5’-CATCAGCGTAAATGGGGATT

5’-TCGACTTTCCATCCCACTTC

Pparg

5’-TGTGGGGATAAAGCATCAGGC

5’-CCGGCAGTTAAGATCACACCTAT

Slc1a5

5’-CATCACCATCCTGGTCACAG

5’-CCTTCCACGTTGAGGACAGT
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FIGURES & FIGURE LEGENDS

Figure 1: BC-CM represses PPARG expression and PPAR-mediated transcription. 48hour conditioned media was collected from BC (EO771 or NF639) or control cell lines (EpH4EV, C2C12 or HEK293), centrifuged to pellet large debris, decanted, and diluted in fresh
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complete growth media prior to application on recipient cells. Figure created using BioRender
(A). Pparg mRNA expression in 5 day differentiated C2C12s exposed to 48-hour CM for 24
hours, quantified using qRT-PCR, nCON = 12, nEO771 = 6, nNF639 = 5 (B). mRNA expression of
PPARG target genes in 5 day differentiated C2C12s exposed to 48-hour CM for 2 hours,
quantified using qRT-PCR, nCON = 3, nEO771 = 3 (C). Western blotting analysis of PPARG protein
expression in 5 day differentiated C2C12s exposed to 48-hour CM for 48 hours, normalized to
GAPDH. Error bars represent standard deviation of the mean (D). Quantification of GFP
intensity in HEK-PGFP reporter cells exposed to 48-hour CM, quantified at 0 and 24 hours of
CM exposure. Adjusted p-values represent Holm-Bonferroni adjusted p-values of paired t-tests,
n = 8 per group (E). * p < 0.05, ** p < 0.01
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Figure 2: BC-CM induces mitochondrial dysfunction and lipid accumulation in myotubes.
Assessment of mitochondrial function affected by BC-CM in 2 day differentiated C2C12
myotubes treated with 48-hour CM for 48 hours, quantified using the Seahorse XF Mito Stress
Test. Error bars represent standard deviation of the mean, n = 10 per group. One experiment is
presented, with consistent findings across 4/5 experiments for repression of aerobic ATP
production, but inconsistent findings for other presented parameters across 5 experiments.
Tables represent results of two-way ANOVA. (A). Extra-cellular acidification rate of 2 day
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differentiated C2C12 myotubes treated with 48-hour CM for 48 hours, quantified using the
Seahorse XF Glycolysis Stress Test. Error bars represent standard deviation of the mean, n =
12 per group, except nNF639 = 10 (B). Relative quantitation of mtCOX2 DNA in 5 day
differentiated C2C12s exposed to 48-hour CM for 24 hours, normalized to 18S gDNA, n = 8 per
group (C). Oil red o image quantification from 4 day differentiated C2C12s treated with 48-hour
CM for 72 hours, represented as the fraction of each image stained red with oil red o, n = 8 per
group (D). Representative images from an independent oil red o experiment conducted under
identical conditions to E, 40X magnification (E). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p <
0.0001

Figure 3: BC-CM decreases mitochondrial respiration and electron flow but does not
decrease lipid oxidation.
ATP coupling (A) and electron flow (B) analysis on isolated mitochondria from C2C12 cells
treated with 48-hour CM, quantified using the Seahorse XF bioanalyzer. Error bars represent
standard error of the mean, n=6 per group collected from two duplicate 96 well assay plates
(n=3 per plate). Respiration state data and injection responses are presented for the ATP
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coupling assay. Electron transport complex activity for complexes 1, 2, and 4 is presented, as
well as the injection responses. P-values represent one-way ANOVA of the data with * p < 0.05,
** p < 0.01.

Figure 4: Exogenous PPARG expression rescues BC-CM-induced mitochondrial
dysfunction and lipid accumulation. Western blotting analysis of PPARG expression in
C2C12s infected with lentiviral particles carrying pLenti-C-PPARG2-mGFP-P2A-Puro
(+PPARG2) or pLenti -mGFP-P2A-Puro (CON) after 5 days of differentiation (A). Assessment of
mitochondrial function in 2 day differentiated CON-C2C12 or +PPARG2 cells exposed to 48-

77

hour CM for 48 hours, quantified using the Seahorse XF Mito Stress Test, n = 10 per group.
C2C12 cell lines are noted on the x-axis, and CM treatment conditions are listed above the bar
graphs. Tables represent results of two-way ANOVA. * p < 0.05 for +PPARG2 cell line
compared to CON-C2C12 cell line under same CM condition; # p < 0.05 for CON cell line
treated with BC-CM compared to CON cell line treated with CON-CM (B). Oil red o image
quantification from 4 day differentiated CON or +PPARG2 cells treated with 48-hour CM for 72
hours, represented as the fraction of each image stained red with oil red o, n = 6 per group (C).
Representative images from the experiment quantified in C, 20X magnification (D). * p < 0.05
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Figure 5: PPARG agonist rosiglitazone fails to rescue BC-CM-induced mitochondrial
dysfunction and PPAR repression, but rescues BC-CM-induced lipid accumulation.
Quantification of GFP intensity in HEK-PGFP reporter cells exposed to 10 uM rosiglitazone
(rosi) or DMSO (control), quantified at 0 and 24 hours of drug exposure, n = 3 per group (A).
Quantification of GFP intensity in HEK-PGFP reporter cells exposed to 48-hour CM in the
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presence of 10 µM rosiglitazone, quantified at 0 and 24 hours of CM exposure. Adjusted pvalues represent Holm-Bonferroni adjusted p-values of paired t-tests, n = 4 per group (B).
Assessment of mitochondrial function in 2 day differentiated C2C12s cells exposed to 48-hour
CM +/- rosiglitazone for 48 hours, quantified using the Seahorse XF Mito Stress Test, n = 10 per
group, except nNF639+rosi = 7. Drug treatment conditions are noted on the x-axis, and CM
treatment conditions are listed above the bar graphs. Tables represent results of two-way
ANOVA. # p < 0.05 for DMSO control with BC-CM compared to DMSO control treated with
CON-CM (C). Oil red o image quantification from 4 day differentiated C2C12 cells treated with
48-hour CM for 72 hours, represented as the fraction of each image stained red with oil red o, n
= 8 per group (D).

Figure 6: Summary of Findings. BC-derived factors induce several physiological changes in
target cells in vitro, including mitochondrial dysfunction, lipid accumulation, and repression of
PPAR-mediated transcription (left). The PPARG agonist Rosiglitazone reverses BC-induced
lipid accumulation but does not reverse mitochondrial dysfunction or the observed repression of
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PPAR-mediated transcription (center). Expression of exogenous PPARG2 in myotubes
reverses both BC-induced mitochondrial dysfunction and lipid accumulation. Figure created
using BioRender (right).
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Chapter 4
Pioglitazone administration restores a PPARG-dependent transcriptional network and
ATP levels within skeletal muscles of mice implanted with patient-derived breast tumors.
This manuscript has been published as a preprint within the bioRxiv. doi:
https://doi.org/10.1101/2021.10.04.463044
This manuscript is currently under review for full publication within the Journal of
Cachexia Sarcopenia and Muscle.

Pioglitazone administration restores a PPARG-dependent transcriptional
network and ATP levels within skeletal muscles of mice implanted with
patient-derived breast tumors.

This work is the foundation of my dissertation and my second first author paper. This work
describes the results of two weeks of pioglitazone treatment in BC-PDOX mice. We found that
the administration of pio restored the muscle gene expression patterns of BC-PDOX mice to a
profile resembling muscles of non-tumor bearing NSG control mice. Validation of skeletal
muscle gene expression by qPCR confirmed pioglitazone increased the expression of PPARG
target genes in skeletal muscles. Isolated mitochondria from muscles of BC-PDOX mice treated
with pioglitazone contained greater levels of ATP. There were no differences in body weights,
muscle weights, or tumor volumes in pio vs. vehicle treated BC-PDOX mice.

For this work I completed the majority of experiments, assisted with the interpretation of data,
and was the primary drafter of the manuscript
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Abstract
Background: Fatigue is common in patents with breast cancer (BC), and can occur in patients
with early stage disease and in the absence of muscle wasting (i.e. cachexia). We have
reported transcriptional and proteomic alterations in muscles from BC patients, which are
associated with fatigue. Mice implanted with human BC xenografts recapitulate the muscle
molecular composition changes seen in patients, coupled with a greater rate of contractioninduced fatigue. Multiple bioinformatics platforms in both human and mouse muscles have
identified peroxisome proliferator activated receptor gamma (PPARG) as central to this
phenotype, with multiple PPARG target genes downregulated in response to tumor growth. The
current study tested the hypothesis that the PPARG agonist pioglitazone (pio), a commonly
prescribed diabetes drug, would rescue the transcriptional alterations observed in muscles of
tumor-bearing mice.
Methods: Sixteen female NSG mice were implanted with breast cancer patient-derived
orthotopic xenografts (BC-PDOX) via transplantation of Her2/neu+ human tumor fragments. BCPDOX mice were randomly assigned to a treatment group that received daily oral pio at 30
mg.kg-1 (n=8), or a control group that received a similar volume of vehicle (n=8). Treatment was
initiated when tumors reached a volume of 600mm3, and lasted for 2-weeks. Hindlimb muscles
were isolated from BC-PDOX and non-tumor bearing mice for RNA-sequencing, gene
expression validation, and ATP quantification. Differentially expressed genes (DEGs) in
muscles from BC-PDOX mice relative to non-tumor bearing controls were identified using
DESeq2, and multiple bioinformatics platforms were employed to contextualize the DEGs.
Results: We found that the administration of pio restored the muscle gene expression patterns
of BC-PDOX mice to a profile resembling muscles of non-tumor bearing NSG control mice.
Validation of skeletal muscle gene expression by qPCR confirmed pio increased the expression
of PPARG target genes (p<0.05 in all genes but PPARG p=0.684) in skeletal muscles. Isolated
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mitochondria from muscles of BC-PDOX mice treated with pio contained greater levels of ATP
(mean luminescence 33770 ± 4057 in BC-PDOX vs. 62780 ± 11510 in BC-PDOX PIO,
p=0.045). There were no differences in body weights (p=0.560), muscle weights (Gas p=0.295,
Sol p=0.365, EDL p=0.182, TA p=0.415) or tumor volumes (p=0.885) in pio vs. vehicle treated
BC-PDOX mice.
Conclusions: These data demonstrate that oral pio supplementation rescues the BCassociated downregulation of PPARG target genes in skeletal muscle. Additionally, muscles
from BC-PDOX mice treated with pio had greater levels of ATP, which would be associated a
more fatigue-resistant muscle phenotype. Therefore, we propose that the FDA-approved and
generic diabetes drug, pio, be considered as a supportive therapy for the treatment of BCassociated muscle fatigue.

Keywords: Breast Cancer, Fatigue, Skeletal Muscle, PPAR-Gamma, Mitochondria, Cachexia
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Introduction
Breast cancer (BC) is the most commonly diagnosed cancer and the second leading
cause of cancer-related death in women1. Through increased medical surveillance, the rate of
BC-associated deaths has decreased, especially in women over the age of 50. Greater medical
surveillance and early detection of breast tumors may also be associated with the observation
that BC-patients have a lower prevalence of diagnosed cachexia, defined as weight loss of >5%
body weight, compared to multiple cancer types161,205. Despite the effectiveness of primary
treatments, high 5-year survival rates, and low prevalence of cachexia, BC patients commonly
report debilitating physical impairments including muscle fatigue. In particular, fatigue is
reported by a majority of breast cancer patients, with up to 96% of all BC patients experiencing
this symptom13. Incidence of fatigue contributes to adverse patient outcomes including dose
reduction or treatment cessation of chemotherapy and radiation, increased pain and reduced
quality of life, and higher rates of cancer recurrence21,206. Additionally, there are currently no
effective drug therapies that target cancer-associated fatigue, or the larger cancer cachexia
syndrome 160.
While BC may not be associated with skeletal muscle wasting in the majority of patients,
recent data suggest that breast tumor growth does influence mitochondrial and metabolic
pathways within skeletal muscle that are associated with fatigue124,125. Recent data from our
laboratory in muscle biopsies obtained from BC patients as well as skeletal muscle collected
from mice implanted with patient-derived breast tumors (BC-PDOX) demonstrate aberrant
skeletal muscle gene expression patterns, skeletal muscle mitochondrial dysfunction, and BCassociated fatigue100,124,125. These BC-induced skeletal muscle intrinsic changes are all potential
mechanisms for the fatigue observed in BC patients. Therefore, developing therapies specific to
this skeletal muscle dysfunction may represent an effective strategy, which would be applicable
to the many patients experiencing BC-associated fatigue. Analysis of transcriptional networks
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indicated that the BC-induced downregulation of the transcription factor peroxisome proliferatoractivated receptor gamma (PPARG) was central to this phenotype within the skeletal muscle of
both BC patients and BC-PDOX mice100,124,125. This was of interest as PPARG is a transcription
factor that aids in whole body energy homeostasis via the regulation of genes involved in lipid
metabolism and mitochondrial function132,207. Analysis of these skeletal muscle transcriptional
changes strongly indicated that PPARG is the central regulator of pathways that contribute to
the increased muscle fatigue experienced by patients and BC-PDOX mice100,124,125. In support of
this analysis, we have recently observed that mitochondrial respiration is impaired and
mitochondrial ATP content is decreased in mitochondria isolated from the skeletal muscle of BC
patients and BC-PDOX mice100,125. Importantly, exogenous PPARG protein expression was able
to ameliorate these effects in myogenic cultures in vitro100.
To address the potential BC-associated skeletal muscle mitochondrial dysfunction, we
generated BC-PDOX mice with HER2/neu+ overexpressing tumors and supplemented them with
the PPARG agonist pioglitazone (pio) for two weeks. We hypothesized that pio
supplementation would increase the expression of PPARG target genes within skeletal muscle,
thereby restoring PPARG transcriptional networks and improving mitochondrial function and
ATP production. The data presented herein support a mechanism whereby pio restores PPARG
transcriptional networks, resulting in improved skeletal muscle ATP content in BC-PDOX mice.
This restoration of ATP content may reflect a rescue of mitochondrial function in muscle,
thereby decreasing the fatigue experienced by BC patients. Therefore, pio supplementation in
BC patients represent a supportive therapy that improves overall quality of life by reducing
fatigue experienced by these patients. This reduction in fatigue, in turn, would allow patients to
continue primary tumor directed therapies when they otherwise may not be able to do so,
potentially resulting in improved treatment outcomes.

87

Materials and Methods
BC-PDOX mice. Animal experiments were approved by the West Virginia University
Institutional Animal Care and Use Committee and have therefore been performed in accordance
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later
amendments. BC-PDOX mice were produced by implanting freshly collected breast tumor
tissue into the cleared mammary fat pad of NOD.CG-Prkdscid Il2rgtm1 Wjl/SzJ/ 0557 (NSG) mice
as previously described 208,209. Briefly, female NSG mice were anesthetized with isoflurane and
immobilized prior to surgery. An incision was made in the skin over the lower lateral abdominal
wall and a pocket was opened under the skin to expose the mammary fat pads. A 3 mm long
pocket was created in the mammary fat pad, and a single tumor fragment of 2 mm 3 was placed
into the pocket. Mice were housed at 22oC under a 12-hour light/12-hour dark cycle and
received food and water ad libitum. Each BC-PDOX model produced was authenticated with the
original patient’s biopsy using genomic DNA and short tandem repeat-based PCR amplification
(Arizona University Genomics Core Facility, Tucson, AZ, USA). Routine human and mouse
pathogen screening was performed on original and passaged tissue by Charles River
Laboratories (Wilmington, MA, USA). RNA sequence and whole exome analysis of original
biopsy and passage 1 BC-PDOX further confirm relatedness of samples and stability of
genomic alterations identified in BC patient and corresponding PDOX. Expression of clinically
relevant BC receptors correlate with the original BC biopsy and are routinely tested by WVU
Genetic and Tumor Models (GTM) Core Facility staff.

Pioglitazone preclinical trial with BC-PDOX mice. BC-PDOX mice implanted with Her2/neu+
patient tumors (n = 16) were randomly selected to receive either pio (30mg . kg-1 body weight) or
vehicle supplementation daily for 14 days. Tumor volume was monitored twice per week
throughout the duration of the study using calipers and ultrasound (Vevo 2100). Treatment was
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initiated when each mouse reached a tumor volume of at least 600 mm3. All supplementation
was delivered via oral gavage.

RNA isolation, sequencing, and bioinformatics. Total RNA was isolated from gastrocnemius
muscles of experimental mice (n=4 BC-PDOX; n=4 BC-PDOX PIO; n=3 NSC-Con) using Trizol
(ThermoFisher Scientific, Waltham, MA, USA) and established methods210. RNA purity was
assessed using a NanoDrop spectrophotometer, with 260/280 readings of at least 2.0. RNA
integrity was measured on an Agilent bioanalyzer with an RNA Nano chip. RNA samples had
RNA Integrity Numbers (RIN) >9, indicating high-quality RNA. RNA-Seq libraries were built
using the Stranded mRNA kit from KAPA Biosciences with Illumina compatible adapters. The
concentrations of the completed libraries were quantified with a qubit fluorometer using highsensitivity DNA reagent. Libraries were subsequently run on the bioanalyzer using a highsensitivity DNA chip. Completed libraries were then pooled in equimolar concentrations and
sequenced on 1 lane of the HiSeq 1500 with PE50 bp reads and at least 20 million reads per
sample. MultiQC was utilized for assessment of sequence quality and was found to be high for
all sequenced samples. Salmon was used for quantification of transcript-level reads, with both
gcBias and seqBias set, and libType A211. Differential expression analysis was conducted using
DESeq after summarizing reads to gene-level using tximport. DESeq2 was run with default
parameters with the exception of a filtering step: genes that did not have at least 3 samples with
a count of at least 1 count per million were eliminated. RNA-Seq output was contextualized
using Enrichr and The Broad Institute’s Gene Set Enrichment Analysis (GSEA) tool. Due to an
RNA-processing error just prior to sequencing, final analyses were performed in n=4 BC-PDOX,
n=3 BC-PDOX pio, and n=3 NSG-Con.
Enrichment analyses. Enrichment analyses were conducted using The Broad Institute’s GSEA
tool and Enrichr. Data presented in this article reflect analyses conducted in Enrichr between
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December 20th 2020 and June 7th 2021, and in GSEA in December 2020. Input data for GSEA
included normalized gene expression counts for all genes with at least 1 count per million in at
least 3 samples, with ranking conducted within GSEA using “Signal-to-noise” based ranking.
Reference gene sets included all KEGG v7 pathways212 with at least 15 genes in the pathway in
our gene set. Input data for Enrichr analyses included only the list of significantly differentiallyexpressed genes (adjusted p < 0.05). In Enrichr, all databases were queried per default
settings, with particular interest in ChEA 2016 for transcription factor target enrichment and
2018 databases from the Gene Ontology project for biological process enrichment analyses.
Regarding the “Combined Score” metric reported as a measure of enrichment, this value is
calculated as described previously 213. Briefly, enrichment for a given pathway is first calculated
using the Fisher exact test for many random gene lists to calculate a mean rank list for all
genes. Our list of differentially-expressed genes is then compared to the expected rank, and
mean and standard deviation for the difference between actual and expected rank is calculated.
Combined score can then be calculated using the formula c = log(p)·z, where c is the combined
score, p is the p-value computed using the Fisher exact test, and z is the z-score computed by
assessing the deviation of each gene in our list of differentially-expressed genes from their
corresponding expected rank. Transcription factor analysis from Enrichr is presented using the
ggpubr package in R.
Hierarchical clustering. Hierarchical clustering analysis was conducted by first calculating the
Euclidean residual distance matrix for filtered, normalized, and log-transformed gene expression
counts, then passing the resulting distance matrix to the heatmap.2 function of the gplots R
package for dendrogram generation using the complete linkage method.
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K-means clustering. K-means unsupervised clustering analysis (k = 3, Hartigan-Wong) was
conducted on the matrix of filtered, normalized, and log-transformed gene expression counts
and visualized using the fviz_cluster function of the factoextra R package.

qRT-PCR validation. Total RNA was isolated from gastrocnemius muscles of BC-PDOX (n = 8)
and BC-PDOX PIO (n = 8) mice. 500 ng of cDNA was produced using Invitrogen SuperScript III
First-Strand Synthesis System (ThermoFisher Scientific) according to manufacturer’s protocol.
Relative expression of selected genes was analyzed using SYBR Green PCR Master Mix
(ThermoFisher Scientific) with the Applied Biosystems 7500 Real-Time PCR System
(ThermoFisher Scientific). qRT-PCR primers (Table 1) were designed using Primer3.

Mitochondrial isolation and ATP analysis. Quadriceps muscles from each mouse (n = 8 BCPDOX; n = 8 BC-PDOX PIO) were quickly removed upon euthanasia, and mitochondria were
isolated using the Mammalian Mitochondria Isolation Kit for Tissue & Cultured Cells (BioVision,
Cat. No. K288) according to the manufacturer’s protocol and using previously described
methods100. Mitochondrial pellets were snap frozen and stored at -80C until utilized in ATP
quantification and ATP synthase activity assays. ATP synthase activity was measured in
isolated mitochondria, using an assay coupled with pyruvate kinase, which converts the ADP to
ATP and produces pyruvate from phosphoenolpyruvate. Pyruvate produced by pyruvate kinase
is converted to lactate by lactate dehydrogenase with the oxidation of NADH which is monitored
at 340 nm. Absorbance was measured on a Biotek Synergy HT plate reader (Biotek, Winooski,
VT). The full protocol is included in the supplementary data with additional references included
here214. Mitochondria ATP content was quantified using the ENLITEN® ATP Assay System
Bioluminescence Detection Kit (Promega, Wisconsin, USA, using the manufacturer’s
recommended standard curve for calculation of absolute ATP content from luminescence
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intensity and The FlexStation® 3 Multi-Mode Microplate Reader (Molecular Devices®, CA,
USA). Luminescence values, reflecting ATP content, were normalized to the sample protein
concentration, quantified using the DC™ Protein Assay (Bio-Rad, CA, USA).

Causal Mediation Analysis (CMA). A prior cohort of BC-PDOX mice were used for CMA;
complete data for skeletal muscle responses in this BC-PDOX cohort can be found in124. Modelbased CMA requires the fitting of two separate linear regression (LR) models to the data: a
“mediator model,” where the mediator variable (muscle mass) is regressed on the intervention
variable (tumor), and an “outcome model,” where the outcome variable (muscle fatigue,
presented as AUC) is regressed on the intervention variable while controlling for the mediator.
All data values for the calculation of CMA, including the area under the fatigue curve and
muscle mass, are presented in Supplemental Table 1. Additional covariates can be added to
the LR models to control for their effect on the mediator and/or the outcome variable. These LR
models were then passed to the mediate function of the mediation R-package for calculation of
average causal mediation effect (ACME) and average direct effect (ADE) and their associated
uncertainty estimates over a number of simulations. In this analysis, 10,000 simulations per
CMA were utilized for calculation of quasi-Bayesian 95% confidence intervals. Standard
multiple regression was conducted in R v3.5.0. Two R packages, DescTools v0.99.28 and olsrr
v0.5.2, were utilized for appropriate assumption checking after fitting linear models.
Assumptions tested include the normality of dependent variables, absence of univariate outliers,
non-multicollinearity, homoscedasticity, and absence of regression outliers. No assumptions
were found to be violated. Models tested are summarized as follows:
Mediator LR: EDL mass ~ subgroup (naive, surgical control, tumor-bearing)
Outcome LR: AUC ~ EDL mass + subgroup
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Statistics. GraphPad Prism (V5; RRID: SCR_002798) was utilized to analyze the following data
sets (qPCR, ATP quantification and ATP synthase activity, and animal weights and tumor
volumes). Unless otherwise stated, all statistical tests used were unpaired, two-tailed t tests for
two-group comparisons. When multiple comparisons were used within an experiment, Holm–
Bonferroni correction was applied to adjust P values. Graphs represent data from a single,
independent experiment. All experiments have been repeated at least twice with similar results.
Data are presented as means ± SEM unless otherwise noted; statistical significance was
defined a p<0.05.
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Results
Skeletal muscle gene expression profiles in pio treated BC-PDOX mice. We have
consistently observed the downregulation of a gene network in skeletal muscles from human BC
patients and mice implanted with human tumor xenografts, with the transcription factor PPARG
being central to this downregulated network100,124,125. To specifically target this gene network in
muscle, we administered a PPARG agonist (pio) daily for 14 days in mice implanted with human
Her2/neu+ tumor fragments, starting at a tumor volume of 600mm3 (Fig. 1A). Following daily
oral pio or vehicle administration, gastrocnemius muscles were processed for RNA sequencing
in tumor-bearing animals and tumor-naïve NSG controls (n=4 BC-PDOX; n=3 BC-PDOX PIO,
n=3 NSG-Con). Unsupervised hierarchical clustering analysis of filtered, normalized, and logtransformed RNA-seq data demonstrated that muscular gene expression patterns in 2 of the 3
BC-PDOX PIO mice clustered with non-tumor-bearing NSG-Con mice. A separate cluster was
observed that included 1 of the 3 BC-PDOX PIO mice with the vehicle treated BC-PDOX mice
(Fig. 1B). Furthermore, principal component analysis (PCA) with k-means clustering supported
these observations, with 2 of the 3 BC-PDOX PIO mice clustering with non-tumor bearing NSGCon and separated from the vehicle-treated BC-PDOX mice (Fig. 1C). This analysis suggests
that 2-weeks of pio-supplementation in Her2/neu+ BC-PDOX mice reverses the BC-tumor
associated alterations in muscle gene expression, such that this muscle gene expression is
more similar to muscle from non-tumor-bearing mice.
Pioglitazone reverses skeletal muscle transcriptional profile in BC-PDOX mice.
Differentially-expressed genes (DEGs) in skeletal muscle were identified by comparing BCPDOX PIO mice to non-tumor bearing NSG-Con, as well as BC-PDOX mice to non-tumor NSGCon. A total of 592 DEGs were significantly different in muscles from BC-PDOX mice compared
to muscles from non-tumor NSG-Con mice (adjusted p < 0.05) (Supplementary Table 2).
Conversely, a total of 174 DEGs were identified as significantly different in muscles from BC-
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PDOX PIO mice compared to muscles from non-tumor NSG-Con mice (adjusted p < 0.05)
(Supplementary Table 3). Enrichment analysis for known targets of transcription factors
identified significant enrichment of genes targeted by PPARG, estrogen related receptor beta
(ESRRB), interferon regulatory factor 8 (IRF8), signal transducer and activator of transcription 3
(STAT3), nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1), nuclear
factor E2-related factor 2 (NRF2), and liver X receptor (LXR) in muscles from BC-PDOX mice.
Conversely, in BC-PDOX PIO mice, significant enrichment of genes targeted by NUCKS1 and
BTB and CNC homology 1 (BACH1) was identified. Importantly, genes targeted by PPARG
were not enriched in muscles from BC-PDOX PIO mice (Figure 2A). These data support our
prior publications and demonstrate that growth of human tumor fragments in the BC-PDOX
model is associated with downregulation of a gene network regulated by PPARG124,125. To
further explore the effects of pio administration in our model, muscle gene expression
associated with biological processes was analyzed using Gene Ontology. A total of 58
dysregulated biological processes were identified in muscles from BC-PDOX mice compared to
NSG-Con, while only 17 dysregulated biological processes were identified in muscles from BCPDOX PIO mice. In muscles from BC-PDOX mice, a strong signal for aberrant mitochondrial
function and electron transport chain (ETC) function is evident in the list of dysregulated
biological processes (Table 2); these processes are not identified in muscles from BC-PDOX
PIO mice (Table 2). Gene Set Enrichment Analysis similarly showed significant dysregulation of
genes associated with oxidative phosphorylation in muscles from BC-PDOX mice and reversal
of this observation in muscles of BC-PDOX PIO mice (Fig. 2B). Collectively, our data suggest
that 14 days of oral pio therapy in BC-PDOX mice restored the muscle expression patterns to
patterns more similar to those observed in the muscles of non-tumor bearing NSG-Con mice.
Validation of RNA-Seq profiles in the skeletal muscle of BC-PDOX mice.
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The muscle gene expression of PPARG and several verified PPARG target genes were
quantified by qRT-PCR in muscles from BC-PDOX PIO mice (n=7) and BC-PDOX mice (n=8) to
validate the RNA-Seq analyses. The muscle samples utilized in this validation were a
combination of muscles used in RNA-Seq experiments and independent muscle samples from
BC-PDOX mice. Pio supplementation in BC-PDOX PIO significantly increased the muscle
expression of all PPARG target genes (Cidec, Fabp4, Rbp4, Slc1a5, AdipoQ) compared to
muscles from BC-PDOX vehicle-treated mice (Fig. 3A-E). The expression of PPARG was not
significantly changed by pio treatment, consistent with our previous work124 and the mechanism
of action of pio (Fig 3F). These observations provide support for the use of pio to reverse the
downregulation of this PPARG-associated gene network in skeletal muscle in BC models.
Furthermore, as we have consistently observed downregulation of these PPARG target genes
in skeletal muscles of human BC-patients and in the BC-PDOX model124–126, we propose that
this gene subset may be considered a “biomarker” for BC-associated fatigue in patients with
early stage BC.
Pioglitazone supplementation restores skeletal muscle ATP content and ATP synthase
activity.
Live mitochondria were isolated from the quadriceps muscle of BC-PDOX PIO (n = 8) and BCPDOX (n = 8) mice and were processed for the quantification of ATP content as well as
evaluation of ATP synthase enzyme activity. We found that skeletal muscle mitochondria from
BC-PDOX PIO mice had a greater ATP content compared to vehicle treated BC-PDOX mice
(Fig. 4A). Similarly, the activity of ATP synthase was significantly greater in mitochondria from
BC-PDOX PIO mice compared to mitochondria from BC-PDOX mice (Fig. 4B), an observation
consistent with the increased overall ATP content. These data indicate that skeletal muscle ATP
and ATP synthase activity may be directly related to increased expression of PPARG target
genes in skeletal muscle. Furthermore, these data suggest that pio supplementation may
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benefit patients with BC-associated muscle fatigue by improving ATP availability within skeletal
muscle.
Characteristics of BC-PDOX mice following pio supplementation.

Tumor growth

progressed linearly during the 2-weeks of pio supplementation, with no differences observed in
BC-PDOX mice compared to BC-PDOX PIO mice (Fig 5A). Body weight remained consistent
during the 2-weeks of pio supplementation, with no differences between BC-PDOX mice and
BC-PDOX PIO mice (Fig 5B). At the time of euthanasia, no differences were observed in the
tumor weight of BC-PDOX mice compared to BC-PDOX PIO mice (Fig 5C). Similarly, no
differences were observed in the tumor-free body weight of BC-PDOX mice compared to BCPDOX PIO mice at euthanasia (Fig 5D). Skeletal muscle mass for selected hindlimb muscles,
including the gastrocnemius, solues, tibialis anterior, and extensor digitorum longus, were not
different when comparing BC-PDOX mice to BC-PDOX PIO mice at euthanasia. Collectively,
these data support our prior observations, that human breast tumor growth in the BC-PDOX
model is not associated with significant body weight loss or muscle wasting. Furthermore, these
data suggest that 2 weeks of daily pio supplementation does not affect tumor growth in the BCPDOX model.
Skeletal muscle fatigue in BC-PDOX mice is not a function of cachexia.
A consistent observation of the BC-PDOX model has been a greater rate of muscle fatigue
without concomitant muscle wasting100,124,125. This phenotype resembles observations in
patients with BC124 but differs from other murine models in which muscle fatigue is documented
with associated muscle wasting161,215,216 To statistically evaluate the contribution of changes in
muscle mass to muscle fatigue in our model, causal mediation analysis (CMA) was performed in
a previous cohort of muscles from BC-PDOX mice (n = 6) using ex vivo muscle fatigue
methodology124 (Fig. 6A). Muscles from naive NSG mice (n = 7) and mice that were implanted
with BC-PDOXs that did not engraft (n = 9) were used as controls for the CMA analysis. Three
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different models of CMA were used to calculate the average direct effects (ADE) of tumor
growth on muscle fatigue and the average causal mediator effects (ACME) of muscle mass on
muscle fatigue in our model. In the three different CMA models tested, there were significant
values for the direct effect (ADE) of tumor growth on the muscle fatigue response, with a
negative effect size in all cases, indicating that tumor growth results in a decreased area under
the curve value that reflects increased fatigability (Table 4). However, muscle mass was not a
significant mediator (ACME) of the muscle fatigue response. The ADE was strongest when
comparing the BC-PDOX mice and the naive control mice (Fig. 6B), while the comparison of
BC-PDOX mice to surgical controls reached a p-value equal to 0.05 (Fig. 6C). When both
control groups were combined into a single group, the ADE was highly significant (Fig. 6D).
This statistical analysis suggests that tumor growth in the BC-PDOX mouse model directly
contributes to the observed greater muscle fatigue and that loss of muscle mass is likely not a
mediator of muscle fatigue in this mouse model of BC.
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Discussion
According to the latest statistics from the National Cancer Institute, approximately 13%
of women will be diagnosed with BC at some point in their lives, and as of 2018, approximately
3.6 million women were living with BC in the United States217. Improved BC surveillance has
contributed to a lower percentage of BC-patients presenting with metastatic disease at the time
of diagnosis, and primary BC treatments are becoming increasingly effective, with 5-year
survival rates of over 90% from 2011-2017 217. While these statistics are promising, the vast
majority of women diagnosed with BC experience cancer-related fatigue, and cancer-related
fatigue is known to contribute to adverse outcomes by reducing a patient’s physical and
psychological tolerance for anti-cancer therapies such as chemotherapy and radiation13,21,36,218.
Therefore, supportive therapies specifically targeting fatigue could improve both quality of life
and survival in BC. While the incidence of fatigue in BC patients is well-known, clinical diagnosis
and intervention for fatigue occurs infrequently. This may reflect the assumption that cancerrelated muscle fatigue is causally linked to the broader paraneoplastic syndrome known as
cancer cachexia. This is of particular relevance to BC patients, as incidence of frank cachexia,
defined as weight loss exceeding 5% of body weight, is quite low in BC161,205. Therefore, any
potentially targetable mechanism underlying fatigue that is intrinsic to skeletal muscle remains
unaddressed, as interventions are typically only prescribed for patients with cachexia-induced
weight loss. This discrepancy highlights the need to address the unique mechanisms that
contribute to BC-associated fatigue in the absence of frank cachexia, with the goal of early
diagnosis and intervention aimed at improving overall treatment outcomes.
Data from our laboratory in muscle from human BC patients and the BC-PDOX mouse
model have identified a BC-induced skeletal muscle phenotype that includes widespread
transcriptional changes, mitochondrial dysfunction, and fatigue100,124–126. These studies have
consistently identified downregulation of PPARG as central to this phenotype, an observation
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that is independent of BC molecular subtype (i.e. luminal, triple negative, Her2/neu+) and
exposure to tumor-directed treatments (i.e. chemotherapy, radiation) 125. We hypothesized that
supplementation with the PPARG agonist pio would increase the skeletal muscle expression of
PPARG target genes involved in mitochondrial regulatory networks, thereby potentially
improving BC-associated fatigue. In vehicle-treated BC-PDOX mice, we once again identified
downregulation of gene networks regulated by PPARG, but these changes were not identified in
BC-PDOX PIO mice following 2 weeks of pio supplementation. Furthermore, gene expression
patterns in muscles from BC-PDOX PIO were restored to the expression patterns of muscles
from non-tumor bearing NSG-Con mice. Gene ontology analysis identified 58 dysregulated
biological pathways in muscles from vehicle-treated BC-PDOX mice compared to NSG-Con,
while only 17 dysregulated biological processes were identified in muscles of BC-PDOX PIO
mice. Among these identified biological processes, only vehicle-treated BC-PDOX mice
exhibited a signal for aberrant mitochondrial function and oxidative phosphorylation, with
correction of this in BC-PDOX PIO mice. Finally, we observed both increased ATP and ATP
synthase activity in the mitochondria of BC-PDOX PIO mice, providing direct support for the role
of pio in improving skeletal muscle mitochondrial function in our BC-PDOX model. Collectively,
our data support a reversal of the BC-associated molecular alterations in skeletal muscle with
short-term pio supplementation; an observation that would be consistent with an improvement in
cancer-associated fatigue.
The underlying mechanisms of cancer-associated fatigue are not well characterized. The
ability of tumors to induce structural, histopathological, and molecular changes in distant tissues
is becoming increasingly recognized219, and tumor growth induces systemic metabolic changes
including the development of insulin resistance220, and altered glucose and lipid metabolism221.
The organ system that is primarily involved in the regulation of these metabolic processes is the
skeletal muscle, and previous studies have described BC-induced skeletal muscle
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transcriptional and mitochondrial changes and associated fatigue100,124. The link between
systemic skeletal muscle changes and localized breast tumor growth may be the function of
PPARG, a nuclear transcription factor that has demonstrated roles in whole body energy
regulation, regulation of insulin sensitivity, lipid metabolism and transport, and glucose
metabolism132,207. We have consistently demonstrated that a systemic consequence of breast
tumor growth is the downregulation of PPARG in skeletal muscle124,125, and this phenotype can
also be induced by applying isolated BC- derived factors to skeletal muscle cells in vitro100. This
interaction results in the aberrant transcription of muscle mitochondrial genes and concomitant
mitochondrial dysfunction. Proteomics performed on the muscle of BC patients with Her2/neu+
tumors has demonstrated that nearly every protein involved in the mitochondrial ETC is
downregulated relative to women without BC, and this is accompanied by decreased
mitochondrial ATP content125. Additional studies have supported this mitochondrial dysfunction,
as BC conditioned media applied to C2C12 myotubes has been shown to decrease
mitochondrial respiration and electron flow100, which can be reversed by exogenous expression
of PPARG. PPARG as a therapeutic target has also been shown to rescue mitochondrial
dysfunction in a number of neurological disorders, including ALS144, and Huntington’s
disease146. In a model of Alzheimer’s disease, PPARG agonist treatment increased
mitochondrial biogenesis and improved glucose utilization145. Additionally rosiglitazone
treatment increased mitochondrial biogenesis, increased oxygen consumption, increased
mitochondrial mass, ΔΨm, mtDNA copy number, decreased autophagy and suppressed free
radical generation in a model of Parkinson’s disease147. Pioglitazone also has a well-established
role in the treatment of type 2 diabetes, and has been shown to increase the expression of
skeletal muscle mitochondrial genes143, improve mitochondrial oxidative function148, and correct
dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis149. In support
of the mechanisms demonstrated in these previous studies, the current study demonstrates
therapeutically targeting PPARG in BC with pio is sufficient to restore muscle gene expression
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patterns to that observed in muscles from non-tumor bearing control mice. This is particularly
evident through the restoration of the transcription of genes involved in pathways associated
with oxidative phosphorylation. This transcriptional restoration is accompanied by increased
mitochondrial ATP content and ATP synthase activity. Given the relationship between proper
skeletal muscle metabolic function and ATP generation, to the incidence of fatigue, and the role
of pio and other PPARG agonists in improving mitochondrial function in other diseases, we
suggest that pio be considered a promising candidate for the amelioration of fatigue in patients
with BC.
The use of biomarkers is common in many cancers, and these typically constitute a
biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or
abnormal process222. Biomarkers have many potential applications in clinical oncology, including
risk assessment, screening, diagnosis, determination of prognosis, prediction of response to
treatment, and monitoring of progression of disease. There are a tremendous variety of
biomarkers, which can include proteins, nucleic acids, antibodies, and peptides. For example,
the expression of BRCA is a well-known biomarker in breast cancer223. We have identified a
PPARG target gene panel (FABP4, CIDEC, SLC1a5, RBP4) that is consistently downregulated
in skeletal muscle from BC patients, as well as multiple cohorts of BC-PDOX mice124–126.
Further, these results have remained consistent across all breast tumor molecular subtypes,
and independent of exposure to chemotherapy or radiation125. We have demonstrated that the
altered gene expression patterns and associated mitochondrial dysfunction and muscle fatigue
occurs in the absence of weight loss. Therefore, we propose that the identified PPARG target
gene panel (FABP4, CIDEC, SLC1a5, RBP4) be considered as a diagnostic biomarker for BCassociated skeletal muscle fatigue in weight stable patients with early stage disease.
Causal mediation analysis is a statistical technique that is based on causal effects,
makes certain assumptions in the modeling explicit, and may be applied to nonparametric or
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curvilinear data224,225. The statistical modeling allows one to control for the effects on a
confounding mediator on the outcome variable being measured224. For example, a recent study
used CMA to provide an unbiased estimate of the effect of muscle hypertrophy on overall
muscle strength levels in response to resistance training224. In the current study, we utilized
CMA to estimate the effects of muscle mass loss (i.e. cachexia) on the rate of muscle fatigue in
response to breast tumor growth in our BC-PDOX model. Our initial statistical analysis
comprised 3 different CMA models based on data acquired in two cohorts of control mice. The
CMA analysis presented in this work suggests that breast cancer tumor growth contributes
directly to fatigue, and that muscle mass is not likely a mediator of muscle fatigue in BC-PDOX
mice. Importantly, these analyses were statistically significant for all three models tested with
associated negative effect sizes, providing evidence that breast tumor growth directly
contributes to the rate of muscle fatigue and that muscle mass loss is not a confounding
mediator of this relationship. These data in the BC-PDOX model are reflective of the clinical
observation that while cachexia is relatively rare in BC-patients, fatigue is often one of the first
recognized symptoms of BC, and is often present prior to a BC diagnosis161.
Overall, the data presented in this study support the therapeutic potential of pio for the
treatment of BC-induced muscle fatigue through the restoration of skeletal muscle gene
expression patterns and mitochondrial function. A limitation of the study is that skeletal muscle
fatigability was not directly measured following the pio treatment; however, this will be assessed
in a future cohort of BC-PDOX mice. We expect that the increased mitochondrial ATP content
and ATP synthase activity demonstrated with pio treatment in the current study will contribute to
a reduction in muscle fatigue in our model. In conclusion, we have demonstrated that the
PPARG agonist pio, is capable of reversing the expected gene expression patterns in the
skeletal muscle of PDOX mice, as well as improving ATP availability in muscle. With this, further
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studies are warranted to determine whether pio can directly improve skeletal muscle fatigue and
provide quality of life benefits to BC patients.
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FIGURES & FIGURE LEGENDS

Figure 1: Skeletal muscle gene expression profiles in pio treated BC-PDOX mice. BCPDOX mice were generated by implanting NSG-Con mice with human Her2/neu+ tumor
fragments. Mice were randomly divided into two groups, with one group receiving
supplementation of oral pio administered for 14 days (30mg/kg-1/day), and the second group
receiving vehicle. Treatment was initiated once a tumor volume of 600mm3 was recorded, and
all mice received oral gavage for a period of 4 weeks (A). Following 4 weeks of treatment,
gastrocnemius muscles from BC-PDOX PIO (n=3) and BC-PDOX (n=4) treated mice were
processed for RNA sequencing and compared to gastrocnemius muscle from tumor-naïve
animals (n=3 NSG-Con). Unsupervised hierarchical clustering was conducted on normalized,
filtered, and log-transformed RNA-seq gene expression data in muscle from study mice, with
treatment group denoted by color (B). Principal component analysis was conducted on
normalized, filtered, and log-transformed RNA-seq gene expression data in muscle from study
mice with k-means (k = 3, Hartigan-Wong) clustering, with clusters denoted by point color (C).
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Figure 2: Pioglitazone reverses skeletal muscle transcriptional changes in BC-PDOX
mice. Differentially-expressed genes (DEGs) in skeletal muscle were identified. Significantly
enriched (adjusted p < 0.05) transcription factors in BC-PDOX group vs NSG-Con (left) and in
BC-PDOX PIO group vs NSG-Con (right), querying ChEA 2016 transcription factor gene sets
via Enrichr (A). Heatmap representing gene expression z-scores of genes within KEGG
Oxidative Phosphorylation pathway (hsa00190) in individual mice from BC-PDOX vs NSG-Con
(top) and BC-PDOX PIO vs NSG-Con (bottom), queried via GSEA, with treatment group
denoted by color. Individual genes are ordered from left to right according to “signal-to-noise”
based ranking per GSEA’s algorithm (B).
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Figure 3: Validation of RNA-Seq profiles in the skeletal muscle of BC-PDOX mice. The
gene expression of PPARG and several previously verified PPARG target genes were validated
by qRT-PCR in the same samples used in RNA-Seq (n = 4 BC-PDOX PIO, n = 4 BC-PDOX) as
well as in skeletal muscle from a new cohort of BC-PDOX mice (n = 4 BC-PDOX PIO, n = 4 BCPDOX). PPARG target genes expression (AdipoQ, Cidec, Fabp4, Rbp4, Slc1a5,PPARG)
compared to vehicle-treated mice (A-F) in both cohorts. 3 technical replicates of each sample
were used for each gene assayed, and results were replicated across 2 individual plates.
Adjusted p-values represent Holm-Bonferroni adjusted p-values of paired t-tests, n = 8 per
group, all values are means ± SEM. * p < 0.05, ** p < 0.01, *** p <0.001.
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Figure 4: Pioglitazone supplementation restores skeletal muscle ATP and ATP synthase
activity. Live mitochondria were isolated form the quadriceps muscle of BC-PDOX PIO (n = 8)
and BC-PDOX (n = 8) treated BC-PDOX mice. Luminescence intensity was calculated for the
quantification of ATP content (A). ATP synthase activity was measured (B) using a
spectrophotometric assay. Absorbance was measured on a Biotek Synergy HT plate reader
(Biotek, Winooski, VT) ETC Complex V Specific Activity (nmol min-1 mg-1) = (△ Absorbance/min
x 1,000) / [(extinction coefficient x volume of sample used in ml) x (sample protein concentration
in mg ml-1)] where extinction coefficient for NADH is 6.2 mM-1 cm-1. ATP content and ATP
synthase activity in the BC-PDOX PIO treated mitochondria was compared to BC-PDOX
controls using the Mann-Whitney U test, n = 8 per group, all values are means ± SEM. * p <
0.05.
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Figure 5: Characteristics of BC-PDOX mice following pio supplementation. Tumor
volumes and body weights of BC-PDOX mice were tracked throughout the study, and muscle
weights were obtained upon euthanasia. The rates of tumor growth (A) and body weight change
(B), final tumor volumes (C) final body weights (D), and individual muscle weights (E) were
recorded. Adjusted p-values represent Holm-Bonferroni adjusted p-values of paired t-tests, n =
8 per group, all values are means ± SEM. Linear regression was performed to calculate the
slopes in (A and B).
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Figure 6: Skeletal muscle fatigue in BC-PDOX mice is not a function of cachexia. Causal
mediation analysis (CMA) was performed in a previous cohort of BC-PDOX mice (n = 6) (A).
Muscles from naïve NSG-Con mice (n = 7, naïve controls) and mice implanted with BC-PDOXs
that did not engraft (n = 9, surgical controls) were used as controls for the CMA analysis. The
ADE was calculated comparing the BC-PDOX mice and the naïve control mice (B), while the
comparison of BC-PDOX mice to surgical controls reached a p-value equal to 0.05 (C). Both
groups combined into a single group is shown in (D).
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Table 1: BC-PDOX Dysregulated Biological Processes
All significantly enriched biological processes (Benjamin-Hochberg adjusted p-value < 0.05) in
the set of differentially expressed genes in BC-PDOX vs. NSG-Con mice, from Gene Ontology
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Project Biological Processes 2018 queried via Enricher. Odds ratio and associated p-value for
enrichment was computed using Fisher exact test. Combined Score represents a second way of
computing enrichment, described under Methods and referenced in213 . Higher Combined
Scores and higher Odds Ratios indicate a greater degree of enrichment.
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Table 2: BC-PDOX PIO Dysregulated Biological Processes
All significantly enriched biological processes (Benjamin-Hochberg adjusted p-value < 0.05) in
the set of differentially expressed genes in BC-PDOX PIO vs. NSG-Con mice, from Gene
Ontology Project Biological Processes 2018 queried via Enricher. Odds ratio and associated pvalue for enrichment was computed using Fisher exact test. Combined Score represents a
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second way of computing enrichment, described under Methods and referenced in213 . Higher
Combined Scores and higher Odds Ratios indicate a greater degree of enrichment.
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Chapter 5
Breast Cancer-Derived Exosomes and miRNAs mediate
associated PPARG downregulation and oxidative
dysfunction.
Introduction
The data presented in this chapter represent our current characterization of breast tumorderived factors as the mechanistic link between breast tumor growth and the skeletal muscle
phenotype we have described. According to our hypothesis, these breast cancer-derived factors
include mediators that are capable of inducing the observed downregulation of PPARG within
skeletal muscle, ultimately leading to the transcriptional and mitochondrial dysfunction. As
previously discussed, our in vitro work indicates that the observed phenotype is influenced by
mediators outside of immune and stromal cell interactions. We thus hypothesized that exosomes
and exosomal derived miRNAs could be the mechanism leading to the downregulation of PPARG,
as similar mechanisms have been recently described in breast cancer.
The concept of the tumor macroenvironment has gained attention in recent years, and
examines how a tumor interacts with distant tissues and organs, and how metabolism in these
organs may be changes in response to tumor-derived factors. It is established that tumors may
cause systemic effects by releasing soluble factors into the blood or lymph vessels 165. The drive
to sustain cellular proliferation is perhaps the main driver of this process. The tumor first begins
to model the surrounding environment, or microenvironment, via autocrine and paracrine
signaling, and chemokine release, which among other things results in tumor directed
angiogenesis166. The newly synthesized blood vessels are able to contribute to the delivery of
oxygen and nutrients to the tumor, promoting growth, while simultaneously allowing the tumor to
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release a wide range of factors into the bloodstream that may ultimately target many peripheral
tissues.
In paraneoplastic conditions such as cancer cachexia, this connection between the tumor
and bloodstream may represent a key event that leads to the metabolic changes described in
peripheral tissue in our work and others. The metabolism of the tumor macroenvironment may
create the conditions that allow for the mobilization of macronutrients, substrates, and other raw
materials needed for the growth and maintenance of the tumor. Evidence suggests that this
comes at the expense of normal metabolic control and homeostasis in target organs, such as the
skeletal muscle167,168. While the etiology of fatigue in breast cancer appears to be related to altered
glucose, lipid, and mitochondrial metabolism within the skeletal muscle, the mechanisms by which
breast tumor induce these changes remain unclear.
The role of tumor-derived extracellular vesicles in mediating cachexia is being increasingly
studied. Extracellular vesicles include exosomes and microvesicles, and are involved in cellular
communication, immune response, tissue repair, epigenetic regulation, and in various diseases
including cancer169. Exosomes can act in autocrine, paracrine, and endocrine signaling, making
them potential mediators of the systemic changes observed in cancer cachexia associated
metabolic changes. To briefly describe the biology of exosomes, they are a type of extracellular
vesicle than contains constituents from the cells that synthesize and secrete them. These
constituents include protein, DNA, RNA, lipid, metabolites, and miRNA178. Exosomes have a size
range of approximately 40nm to 160nm in diameter, and are endosomal in origin. Exosomes are
generated in a process that involves the invagination of the plasma membrane and the formation
of intracellular multivesicular bodies that are ultimately secreted as exosomes. These bodies can
then be further processed by the trans-Golgi network and the endoplasmic reticulum which
contribute to their formation and also the content of the exosome179. Tumor cells exhibit enhanced
exosome release for communication with both local and distant cells. Exosomes are involved in
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all of the major hallmarks of cancer, including sustained proliferation, angiogenesis, immune
system evasion, genomic instability, apoptosis resistance, deregulated cellular energetics,
invasion and metastasis190,191. While evidence of exosome/miRNA induced phenotypes is
accumulating, the mechanisms remain poorly understood. One possibility is the ability of
exosomal miRNA to directly target proteins within the skeletal muscle resulting in the observed
metabolic dysfunction. We have demonstrated evidence that one such target in breast cancer is
skeletal muscle PPARG, which is consistently down-regulated in skeletal muscle across all breast
cancer subtypes125. The miRNA mediated degradation of skeletal muscle PPARG in breast
cancer, and subsequent transcriptional changes remains an attractive hypothesis. The regulation
of PPARG by miRNA has been studied in the context of cancer, and metabolic disorders. Several
studies have examined the role of miR-27 in PPARG regulation, and have demonstrated that this
miRNA targets PPARG resulting in decreased expression. A study from Kin et al. revealed that
miR-27a is involved in adipocyte differentiation by binding to the PPARG 3'-UTR, resulting in
downregulation of PPARG expression199. Lin et al. demonstrated similar results, showing that the
miR-27 gene family is downregulated during adipogenic differentiation, and overexpression of
miR-27 resulted in the inhibition of adipocyte formation200. Despite these publications, there
remains a general gap in knowledge concerning the phenotypes observed in peripheral tissues
exposed to breast tumors, and the mechanisms by which breast cancer may induce them. The
metabolic and mitochondrial dysfunction that we have observed in skeletal muscle of breast
cancer models is slowly being recognized for the potential to contribute to the overall phenotype
of breast cancer-induced fatigue. The work presented herein is focused on characterizing these
changes and applying therapeutic strategies in the form of exosome blockade.
Methods
To test our hypothesis that tumor-derived factors such as exosomes could lead to the
observed phenotypes, we utilized a model system in which we first characterized the expression
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of miRNAs contained within the exosomes of control (HEK) and breast cancer (MDA-MB-231)
cell lines..
Cell Culture
Cell lines used include HEK293 (human embryonic kidney), MDA-MB-231 (Human TNBC) and
C2C12 (murine myoblasts). All cell lines were obtained from ATCC (Virginia). All cell lines were
cultured in DMEM (ThermoFisher, Massachusetts) supplemented with 10% heat-inactivated fetal
bovine serum (Atlanta Biologicals, Georgia) and penicillin-streptomycin (ThermoFisher) at 37°C
with 5% CO2. C2C12 myoblast cells were allowed to differentiate into myotubes prior to oxidative
function testing. Myoblasts were grown to 70-80% confluency and stimulated to differentiate by
applying differentiation media (DMEM supplemented with 2% horse serum and penicillinstreptomycin). Oxidative function was measured using an Agilent Seahorse bioanalyzer after 48
hours of differentiation.
Exosome Isolation
Exosomes were isolated and collected from the conditioned media of cell lines following 48 hours
of growth in serum free media. Ultracentrifugation was used to isolated the exosome pellets
according to the following protocol. 1. 300xg for 10min. 2. 2600xg for 10min. 3. 10000xg for 60min.
Remove supernatants for 1-3. 4. 100000xg for 2 hours. All spins at 4C. Following step 4, the
exosome pellet was resuspended in 500uL of ice-cold PBS and processed or stored at -80C.
RNA Isolation from Exosomes and Characterization
Total RNA was isolated from exosome pellets using a standard Trizol based RNA extraction
protocol. RNA quality and quantity were assessed using a Nanodrop and isolated RNA was stored
at -80C prior to small RNA sequencing analysis. The isolation of exosomes was confirmed using
Nanosight particle size analysis, and the particles that were isolated corresponded to the
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expected size of exosomes.
Functional Assays
The effect of breast cancer-derived exosomes on skeletal muscle was evaluated by assessing
C2C12 oxidative function via seahorse bioanalyzer. Three conditions were developed using our
Normal conditioned media exposure paradigm of 48 hours of conditioning prior to
supplementation to C2C12s. First, we used a control conditioned media under normal conditions.
Next, we depleted exosomes from the conditioned media of MDA-MB-231 breast cancer cells via
one of two methods. First, we removed them mechanically via ultracentrifugation, and second,
we removed them using an inhibitor of exosome biosynthesis and release (GW4869). Media from
these three conditions was then applied to C2C12s following 48 hours, and oxidative function was
assessed via mitochondrial stress test after an additional 48 hours of exposure.
Next, we obtained a miR-27a-3p mimic (miRVana) and transfected HEK cells according to the
manufacturers protocol. We evaluated the oxidative function of these cells via a mitochondrial
stress test following 48 hours of exposure.
Results
This sequencing data demonstrated the expression profile of breast cancer miRNA was
quite distinct from the control cell line Fig 5.1 (B). Differential gene expression analysis Fig 5.1
(C) identified the top differentially expressed miRNAs, including one, 27a-3p, that previous in silico
analyses had predicted to be upregulated in breast cancer. This was intriguing, as PPARG is a
verified target of 27a-3p, and is downregulated by increased expression of this miRNA.
Following this characterization, we attempted to recapitulate the oxidative dysfunction
previously demonstrated by exposure of skeletal to breast cancer conditioned media. In this
experiment, we conditioned media with MDA-MB-231 breast cancer cells, and then applied this
conditioned media to C2C12 skeletal muscle myoblasts in one of three conditions. The first was
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the control non-modified conditioned media, the second was breast cancer conditioned media
that had the exosomes physically removed via ultracentrifugation, and the third was breast cancer
conditioned media that was collected from cells treated with a drug that blocks exosome
biosynthesis and release. Fig 5.2 demonstrates the results of this experiment, and shows that
both exosome depleted groups have significantly higher ATP production than the control exosome
containing group. We then took the experiment one step further, by exposing control cells to a
miRNA mimetic that was specific for miRNA-27a-3p. Exposure to the mimic alone demonstrated
similar results as exposure to breast cancer-derived exosomes. ATP production in HEK cells
exposed to the mimic was significantly reduced, and qRT-PCR demonstrated that exposure to
the mimic resulted in a 2-fold reduction in PPARG mRNA Fig 5.3.
Discussion
Overall, these preliminary data demonstrate that breast cancer-derived exosomes are
able to induce the oxidative dysfunction that we have previously observed in skeletal muscle
exposed to breast cancer conditioned media. Further, these results can be replicated by
modulation of PPARG targeting miRNA. These results support our original hypothesis, and will
serve as the basis for future studies that will further characterize these mechanisms.
The results of these experiments are promising, but there are several limitations and
points of discussion. First, we need to evaluate the exosomal miRNA profile of additional breast
cancer subtypes to determine if a similar expression profile exists. This would be expected given
the overall similarity of pathway dysregulation among breast cancer molecular subtypes, however
there is the potential for different mechanisms of regulation. For example, some subtypes may
contain miRNA that directly target PPARG, whereas others may contain miRNA that target
PPARG coregulators. Next, it is necessary to repeat the miRNA mimic experiment using a
negative control to confirm the results of the initial trial. A negative control was used during the
initial experiment, however the cells transfected with the control experienced widespread death,
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perhaps due to experimental error. Future experiments should examine the RNA and protein
expression of PPARG and PPARG targets following depletion of exosomes.
Further future studies will include the characterization of the miRNA profile of exosomes
isolated from the serum of both breast cancer PDOX mice and breast cancer patients participating
in our ongoing clinical trial. Additional experiments will aim to modulate exosomes and miRNA
within our animal models, with the ultimate goal of developing a therapeutic strategy to target
either breast tumor exosomal synthesis and release, or miRNA packaging or function. Work is
ongoing to examine the potential role of miRNA sponging in breast cancer and control cells, as
miRNA sponging is a promising therapeutic strategy for miRNA mediated mechanisms of disease.
It is likely that future studies will determine the regulation of PPARG via exosomes and miRNA is
impacted by additional factors and/or miRNA’s beyond miRNA-27a-3p, but this work represents
the first step of characterizing a likely mechanism underlying our observed phenotype.
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Fig 5.1: Isolation of exosomes was verified through Nanosight analysis (A). Sequencing of small
RNA isolated from breast cancer and HEK exosomes demonstrated distinct transcriptional
profiles and differentially regulated miRNAs between the two groups (B &C). Differential miRNA
included 27a-3p, previously predicted to be upregulated in breast cancer with known targeting
ability for PPARG.
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Fig 5.2: Exosome depletion improves ATP production in C2C12 cells exposed to breast cancer
conditioned media. Mito stress respiration analysis was performed using an Agilent bioanalyzer,
on C2C12 skeletal muscle cells that were exposed to breast cancer (MDA-MB-231) conditioned
media for 48 hours. Control media (MDA) as well as conditioned media with exosomes removed
via ultracentrifugation (MDA Exo-) and drug treatment (MDA GW+) was applied.
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Fig 5.3: Oxidative function of HEK cells exposed to miRNA 27a mimic (A-D). PPARG
expression in HEK cells exposed to mir27a mimic.

Exosome depletion improves ATP production in C2C12 cells exposed to breast cancer conditioned
media. Mito stress respiration analysis was performed using an Agilent bioanalyzer, on C2C12 skeletal
muscle cells that were exposed to breast cancer (MDA-MB-231) conditioned media for 48 hours. Control
media (MDA) as well as conditioned media with exosomes removed via ultracentrifugation (MDA Exo-)
and drug treatment (MDA GW+) was applied.
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Chapter 6
Discussion and Conclusions
Breast Cancer, Fatigue, Contributions to the Field and Overall Impact
As researchers in the field of cancer cachexia, a major goal of our lab has always been to
highlight the phenotype of breast-cancer induced fatigue in the absence of muscle wasting. Within
the field, the majority of research has suggested that the deleterious effects and adverse patient
outcomes associated with cancer cachexia are largely due to the loss of skeletal muscle and
adipose tissue mass. There is no doubt that wasting is observed in many patients, it is also true
that the prevalence of this wasting is highly variable depending on the type of cancer, and the
stage of cancer progression. For example, approximately 70% of patients with pancreatic cancer
eventually develop wasting to the point of a cachexia diagnosis, whereas only about 20% of
patients with prostate or breast cancer develop wasting. However, increasing evidence and
discussion within the field indicates that wasting is not the sole consequence of cancer cachexia.
Additionally, wasting often reaches the clinical threshold only after patients have become
refractory to primary treatment and supportive interventions. In breast cancer, perhaps the most
relevant additional consequence of cachexia is fatigue, which is experience by the majority of
breast cancer patients.
The mechanisms that underlie fatigue and wasting are clearly distinct, or perhaps
representative of a spectrum type disorder, in which systemic changes induced by breast cancer
growth induce fatigue prior to eventual wasting. This concept of a spectrum, or staging system is
interesting, as it could potentially be developed to interact with the current cachexia staging
system150. In this system, cachexia is divided into pre-cachexia, cachexia, and refractory
cachexia, in which wasting is generally observed in the cachexia and refractory stages. We posit

126

that the changes in skeletal muscle transcription and mitochondrial function associated with
breast cancer-induced fatigue be considered a symptom of precachexia.
Associating breast cancer-induced fatigue and early-stage cachexia/precachexia is
desirable for several reasons. First, many breast cancer patients begin to experience fatigue
relatively early in the progression of their disease, often before the initial diagnosis and start of
treatment12. A major goal in cancer treatment programs is prevention and early intervention. If
patients and clinicians can integrate recognition of this fatigue into screening programs, a higher
percentage of patients may benefit from early-stage diagnosis. Second, the changes we have
observed in skeletal muscle during breast cancer have implications for systemic metabolic
regulation and energy balance. As we have demonstrated, some of these changes, such as
mitochondrial function and lipid metabolism, may be therapeutically targetable. While the
available data and current experimental design support pioglitazone therapy as a supportive
therapy in breast cancer, the improvement of systemic metabolic control may have tumor directed
effects as well. For example, there is evidence that pioglitazone reduces the proliferative and
invasive capacity of cancer cells in culture227 as well increasing the cytotoxic effectiveness of
traditional therapy228. In our studies, we have not observed any differences in tumor volumes or
rates of growth when supplementing with pioglitazone alone, however the skeletal muscle specific
improvements of the muscle when exposed to pioglitazone are promising. Overall, this could lead
to pioglitazone therapy being recognized as the first anti-cachexia therapeutic, and if therapy is
initiated during precachexia there is potential for synergistic tumor directed efficacy. Finally, our
data demonstrate that the phenotype of breast cancer-induced fatigue and transcriptional
alterations are subtype independent. Therefore, pioglitazone therapy should prove effective for
many breast cancer patients, regardless of the molecular composition of the tumor.
Collectively, the work of the lab and this dissertation work will contribute several advances
to the field of cachexia and breast cancer research. We have characterized a skeletal muscle
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phenotype in breast cancer that is systemic, and reproducible across model systems. A major
point is that this phenotype is independent of breast cancer subtype, prior treatment status, and
weight loss125. This should help to highlight the distinct nature of this phenotype in the context of
cachexia diagnoses. We propose that the incidence of fatigue in precachexia should serve as a
diagnostic for the initiation of supportive therapies. To that end, we have shown that pioglitazone
is effective at rescuing several aspects of this phenotype, including transcriptional alterations and
ATP within the skeletal muscle. Further, the recognition that this therapy should be applicable to
all breast cancer subtypes reinforces the attractiveness of this supplementation. Future studies
will examine the efficacy of pioglitazone treatment in all subtypes, beginning with our recently
approved clinical trial, in which we will begin supplementation of pioglitazone in luminal breast
cancer patients. Ultimately, our goal is to promote clinical recognition of this phenotype, prevent
and/or reverse cancer-associated fatigue, and improve patient quality of life and tolerance to
tumor directed therapies. We look to our ongoing clinical trial to further examine and address
these outcomes. From this discussion of the broader context of this work to the field at large, we
will now examine the specific advances elucidated during the project.
Breast Cancer Induces Skeletal Muscle Transcriptional and Mitochondrial Dysfunction
The research provided in this dissertation serves to examine the response of skeletal
muscle to the growth and pathogenesis of breast cancer. While it has been known that fatigue is
associated with cancer and cancer cachexia, the mechanisms leading to fatigue and sites of this
fatigue (peripheral vs. central) remain poorly understood. Our laboratories examination of this
problem began with the identification of an altered transcriptional profile in the skeletal muscle of
early stage non-metastatic breast cancer patients, and breast tumor bearing mice126. RNAsequencing in muscles of these cohorts first revealed the dysregulation of canonical pathways
involved in oxidative phosphorylation, mitochondrial function, PPAR signaling, and IL-15
signaling. In an extension of this study, of which I am a co-author, we developed the BC-PDOX
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model that ultimately became our model of choice to recapitulate the phenotype we observe in
patients, and demonstrated the presence of peripheral muscle fatigue in this model124. In this
study, bioinformatic analysis of muscle from patients representing all breast cancer molecular
subtypes as well as BC-PDOX mice, revealed the transcriptional alterations observed within
muscle exposed to breast cancer center around the downregulation of a PPARG driven network.
This network is responsible for the expression of myriad genes in metabolic pathways, including
many genes involved in the insulin signaling pathway and in mitochondrial pathways. This insight
was intriguing, as we quickly recognized the potential use of PPARG agonists to stimulate this
pathway and restore these networks.
Upon identification of altered PPARG signaling networks we expanded our patient cohort
and characterized the skeletal muscle gene expression profiles in 33 breast cancer patients
representing all of the breast cancer molecular subtypes125. An important observation was made
when examining the clinical data associated with these patient’s charts. We observed that the
alterations in muscle gene expression in these patients was not associated with prior
chemotherapy or radiation treatments, tumor staging, hormonal treatment, BMI, or change in BMI.
Many of these factors have traditionally been represented to be correlated with cancer associated
fatigue, so these results supported our overall hypothesis stating that fatigue is associated with
muscle intrinsic metabolic changes in response to exposure to tumor-derived circulating factors.
Additionally, these findings suggest that skeletal muscle gene expression changes are not
reflective of a traditional cachectic process, which would largely be related to weight loss. This
study provided further support for a muscle intrinsic mechanism, as proteomics analysis revealed
that almost every complex of the electron transport chain was downregulated in breast cancer.
This corresponded with the finding that there were lower levels of ATP in the skeletal muscles of
breast cancer patients and BC-PDOX mice. This was our first evidence of a direct mechanism
capable of responsibility for the peripheral muscle fatigue we observed in isolated skeletal
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muscles. A reduction in ATP has the potential to directed result in this fatigue, as muscle
contraction relies heavily on ATP at multiple sites of the contractile apparatus and maintenance
of force requires the use and resynthesis of large concentrations of ATP.
These previous studies characterized a strong PPARG-dependent transcriptional
response to breast cancer within skeletal muscle, and pathway analysis predicted dysfunction in
multiple metabolic signaling pathways regulated by PPARG target genes. While the decreased
ATP levels in the muscles of breast cancer patients indicated the potential for mitochondrial
dysfunction, more evidence was needed to characterize the specific metabolic alterations within
skeletal muscle. The work contained in chapter 3 describes elucidation of these changes in an in
vitro model of breast cancer exposure. As our previous work had consistently identified
downregulated PPARG transcriptional function as central to the observed phenotype, we selected
two methods to restore this dysfunction. We generated a PPARG overexpressing C2C12 skeletal
muscle murine cell line, and pharmacologically targeted PPARG transcriptional function with the
agonist rosiglitazone. These cells were then exposed to conditioned media from murine breast
tumor cell lines representing the luminal and Her2/neu+ breast cancer subtypes to test the
hypothesis breast cancer cells secrete a factor that represses PPARG expression and its
transcriptional activity, leading to downregulation of PPARG target genes involved in
mitochondrial function and other metabolic pathways. This work demonstrated that skeletal
muscle cells exposed to breast cancer conditioned media developed a phenotype that included
aberrant intramuscular lipid deposition and mitochondrial oxidative dysfunction100. This
intramuscular lipid deposition is an intriguing phenotype, as it has been previously observed in
patients with cancer229,230 and is associated with the progression of cancer cachexia.
Intramuscular lipid deposition is also observed in type 2 diabetes231, and smoking-induced insulin
resistance232. As the downregulation of PPARG expression and transcriptional activity is
associated with the development of insulin resistance139 and many PPAR transcriptional targets
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are mitochondrial lipid transport proteins233, we hypothesized that a decreased capacity for
mitochondrial lipid import may contribute to the observed phenotype of BC-induced lipid
accumulation, which may then contribute to insulin resistance. However, this lipid accumulation
does not appear to be due to decreased rates of fatty acid oxidation in cells exposed to BC-CM,
as assessed by palmitate stimulated mitochondrial stress assays. This result was somewhat
unexpected, and future studies should aim to further elucidate the mechanisms of this lipid
accumulation. Finally, aberrant intramyocellular lipid deposition can in many cases contribute to
lipotoxicity characterized by the accumulation of toxic lipid intermediates such as diacylglycerols
and ceramides234, increased production of ROS235, and is associated with changes in autophagic
dynamics236,237, all of which are implicated in reduced mitochondrial function within skeletal
muscle. The sum of these observations suggests that skeletal muscle lipotoxicity in breast cancer
could play a major role in the phenotype of BC-induced skeletal muscle fatigue independent of
mitochondrial dysfunction, and future studies should investigate this potential link in greater detail.
The other major findings of this study involved the phenotype of the PPARG
overexpression and drug treated cell lines when exposed to breast cancer conditioned media.
Exogenous PPARG overexpression was sufficient to rescue the mitochondrial dysfunction
observed in these cells, as well as preventing the intramuscular lipid deposition. Rosiglitazone
was also able to prevent the accumulation of lipid but was not able to rescue mitochondrial
function. This result was interesting as it suggests that the observed oxidative dysfunction may
not be related to lipotoxicity, but perhaps directly related to PPARG mediated transcription of
mitochondrial target genes. This was supported by the observation that rosiglitazone was unable
to stimulate activation of the PPAR transcriptional response element. This may have been due to
temporal regulation, as the time course for treatment was only 24 hours in the study, which may
not have allowed for sufficient transcriptional activation and subsequent translation of target
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proteins. While this study was a step forward, questions still remained, including the efficacy of
using PPARG agonists for the treatment of mitochondrial dysfunction in vivo.
The study described in chapter 4 represents the culmination of this dissertation work, and
provides exciting results to serve as a foundation for the future of the lab. In this work, we once
again returned to our BC-PDOX model with mice implanted with Her2/neu+ tumors. We then
supplemented these mice with oral pioglitazone for two weeks and subsequently analyzed
skeletal muscle for RNA sequencing, gene expression and mitochondrial function. We
hypothesized that supplementation with the PPARG agonist pioglitazone would increase the
skeletal muscle expression of PPARG target genes involved in mitochondrial regulatory networks,
thereby potentially improving breast cancer-associated fatigue. In vehicle-treated BC-PDOX
mice, we once again identified downregulation of gene networks regulated by PPARG, but these
changes were not identified in BC-PDOX PIO mice following 2 weeks of pioglitazone
supplementation. Furthermore, gene expression patterns in muscles from BC-PDOX PIO were
restored to the expression patterns of muscles from non-tumor bearing NSG-Con mice.
Furthermore, these changes were once again observed in the absence of changes to muscle
weights.
This result was excellent, as is demonstrated that PPARG agonism was indeed able to
induce transcriptional changes in muscle, a result which was not demonstrated in our in vitro
studies. As previously stated, this may be due to the increased time of supplementation, or
perhaps due to the oral route of administration. An additional possibility is that the pioglitazone
supplementation in vivo is acting at the level of both the skeletal muscle and adipose tissue,
increasing the overall effectiveness. This is supported by the fact that endogenous PPARG
expression levels are relatively low in skeletal muscle under normal conditions, while it is
expressed at very high levels in adipose tissue. If the pioglitazone supplementation is working at
the adipose tissue, it is likely that this may be involved in the improvement of glucose of insulin
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sensitivity at the systemic level. Additionally, pioglitazone may be restoring adipogenesis, thereby
decreasing levels of circulating free fatty acids which may play a role in the pathogenesis of
skeletal muscle in breast cancer. Future studies should aim to further investigate the role of
adipose tissue in the observed phenotypes.
Although we did not investigate the role of adipose tissue in pioglitazone response, we did
observe increased expression of direct PPARG gene targets within the skeletal muscle following
the two-week treatment period. These genes included FABP4, CIDEC, SLC1a5, and RBP4, which
is a panel we have consistently found to be downregulated in skeletal muscle in breast cancer.
We have demonstrated that the altered gene expression patterns and associated mitochondrial
dysfunction and muscle fatigue occurs in the absence of weight loss. Therefore, we propose that
this panel be considered as a diagnostic biomarker for breast cancer-associated skeletal muscle
fatigue in weight stable patients with early stage disease.
Perhaps the most intriguing finding of this work was that 2 weeks of pioglitazone
supplementation was sufficient to increase skeletal muscle ATP content and ATP synthase
activity in breast cancer. Given the relationship between proper skeletal muscle metabolic function
and ATP generation, to the incidence of fatigue, and the role of pioglitazone and other PPARG
agonists in improving mitochondrial function in other diseases, we suggest that pioglitazone be
considered a promising candidate for the amelioration of fatigue in patients with breast cancer.
To expand upon this, we have received approval to begin a clinical trial at WVU to supplement
breast cancer patients with oral pioglitazone for 4 weeks. We will once again evaluate the skeletal
muscle transcriptional response in these patients, as well as evaluating perceptions of fatigue and
circulating factors that may be involved in the mechanisms of skeletal muscle PPARG
downregulation. This trial represents one of the first pharmacological interventions for breast
cancer associated fatigue and metabolic dysfunction, and if successful at improving patient
outcomes could become the first FDA-approved pharmacological intervention for cancer
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cachexia. Ultimately, this translational work represents a major long-term goal of the lab and
should serve as a strong platform for future research.
Tumor-Derived Factors as Potential Mediators of the Observed Phenotype
An important question of the project is the mechanisms by which breast cancer induces
the skeletal muscle phenotype we have observed and characterized. Our hypothesis has always
been that breast tumors secrete a variety of factors that are able to directly target peripheral
organs such as the skeletal muscle, ultimately resulting in the downregulation of target gene or
protein expression. Our in vitro work provided part of this rationale. It is well established that BC
cells can regulate both local and systemic immune functions238,239, and that inflammatory signaling
is intrinsically linked to cancer-associated skeletal muscle wasting150,173. Therefore, a reasonable
assumption is that breast cancer’s influence on immune cells is the cause of BC-induced skeletal
muscle fatigue. Our in vitro study contradicts this assumption by showing that breast cancerderived factors can significantly alter mitochondrial function and PPAR activity in skeletal muscle
cells without the involvement of immune or stromal cell mediators, indicating that breast cancer
cells secrete a factor that induces these effects by interacting directly with skeletal muscle.
When examining potential tumor-derived factors that could be responsible for the
downregulation of PPARG within skeletal muscle, exosomes and exosomal miRNA’s emerged as
likely candidates. Exosomal miRNAs have been shown to mediate cachexia in other models190,193,
and as we have demonstrated that our phenotype is directly related to downregulation of PPARG
expression we needed to identify a factor with the potential to mediate this downregulation. To
begin answering these questions, we first had to successfully isolate exosomes from the
conditioned media of breast cancer cell lines and subsequently isolate total RNA from the isolated
exosome pellets. In preliminary experiments we managed to successfully isolate both exosomes
and their constituent RNA, which was used for RNA sequencing enriched for small RNA. When
we analyzed the differentially expression miRNAs we found that miR-27a-3p was consistently
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upregulated in breast cancer derived exosomes. This was intriguing because PPARG is a verified
target of miR-27a-3p and delivery of miR-27a-3p to the skeletal muscle could be sufficient to result
in the observed downregulation. To test this mechanism, we first measured general mitochondrial
oxidative function in C2C12 cells following exposure to isolated breast cancer derived exosomes.
We found that exposure to these exosomes resulted in reduced mitochondrial ATP production
when compared to exposure to breast cancer conditioned media depleted of exosomes. We then
measured ATP production in HEK cells following overexpression of miR-27a-3p and
demonstrated that this overexpression reduced ATP production by almost 50%. We also
demonstrated that exposure to this mimic resulted in a 2-fold reduction in PPARG expression
compared to a no-template control group. While preliminary in nature these results provide
promising support for a mechanism in which tumor-derived exosomal miRNAs are responsible for
the observed phenotype. This project will be the focus of future studies in the lab, and these
mechanisms will be further explored in vivo.
Limitations and Future Directions
Perhaps the biggest limitation of this work was the examination of ex vivo muscle fatigue.
Following the success of the 2-week pioglitazone trial we established a new cohort of BC-PDOX
mice and extended the treatment period to 4 weeks to mimic the design of our approved clinical
trial. Following this trial, we found that we were able to successfully induce PPARG target gene
expression in the pioglitazone treated animals, but were unable to rescue fatigue. There were
also no observed differences in the ATP content of the skeletal muscle following this trial. We had
encountered a similar problem previously and it appears to be related to the rates of tumor growth
and end point tumor volumes, particularly in the vehicle treated mice. We observed that the tumor
volumes in this trial were much lower than the volumes we generated in the 2-week trial.
Therefore, there was difference in fatigability between the vehicle treated and non-tumor bearing
group. According to previous data, it appears our phenotype is only observed once the tumors
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reach a volume of approximately 800mm3, and the tumors in the 4-week vehicle treated group
were ultimately too small to induce the phenotype. Patient-derived xenografts often have quite
variable growth rates, which makes predicting the correct time to begin treatment difficult. We
hypothesized that based on previous rates of growth beginning 4-weeks of treatment at 200mm3
would result in tumor of sufficient size at the end of the trial, but this was not the case. In a future
trial, the methods of PDOX implantation will be changed from a tumor fragment to a cell
suspension, as cell suspensions tend to have more predictable rates of growth.
An additional limitation is the relative lack of data on the role of adipose tissue in mediating
the observed phenotype. While we have characterized the response to breast cancer and
pioglitazone treatment in the skeletal muscle, regulation of PPARG within the adipose tissue has
the potential to have a large impact on the breast cancer induced phenotypes. As we have stated
previously, expression of PPARG in the adipose tissue is significantly higher than within the
skeletal muscle, and if it is being downregulated in a similar way, could have an impact on
systemic consequences such as the development of insulin resistance. Adipose tissue has been
collected from BC-PDOX mice described in these studies, so future work should look to examine
PPARG and target gene expression within adipose tissue.
Finally, the mechanistic work examining exosomes and miRNA are quite preliminary in
nature. While promising, many additional studies will be needed to fully elucidate the roles of
breast cancer-derived exosomes and miRNA play in the skeletal muscle dysfunction and fatigue.
Overall, this dissertation work serves to characterize a unique skeletal muscle transcriptional and
mitochondrial phenotype which likely contributes to the development of breast cancer-associated
fatigue. Pioglitazone has been identified as a promising therapeutic strategy to address this
phenotype, and a recently initiated clinical trial will assess the efficacy of this strategy in breast
cancer patients.
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